

Early minimally invasive image guided endoscopic evacuation of intracerebral haemorrhage (EMINENT-ICH): a randomized controlled trial

Study Type: Other Clinical Trial according to ClinO, Chapter 4
Risk Categorisation: B
Study Registration: Intended primary study registry: ClinicalTrials.gov
 Registration number: **NCT05681988**
 SNCTP registration number: SNCTP000005643
Sponsor: Prof. Dr. med. Raphael Guzman
 Vice Chair, Head of Vascular and Pediatric Neurosurgery
 Department of Neurosurgery, University Hospital Basel
 Spitalstrasse 21, 4031 Basel
Raphael.guzman@usb.ch
Principal Investigator Prof. Dr. med. Jehuda Soleman
 Senior Neurosurgeon, Head of Clinical Research
 Department of Neurosurgery, University Hospital Basel
 Spitalstrasse 21, 4031 Basel
Jehuda.soleman@usb.ch
Sub-Investigators Prof. Dr. med. Urs Fischer
 Chair of Neurology, Head of the Department of Neurology
 Department of Neurology, University Hospital Bern
 Rosenbühlgasse 25, 3010 Bern
urs.fischer@insel.ch
 Dr. med. Tim Hallenberger
 MD PhD Candidate
 Department of Neurosurgery, University Hospital Basel
 Spitalstrasse 21, 4031 Basel
tim.hallenberger@usb.ch
Investigated Intervention: Early minimally invasive image guided endoscopic evacuation of intracerebral haemorrhage
Protocol ID *not applicable*
Version and Date: Version 3.0 (dated 18/07/2024)

CONFIDENTIALITY STATEMENT

Not applicable

PROTOCOL SIGNATURE FORM

Study Title Early minimally invasive image guided endoscopic
 evacuation of intracerebral haemorrhage (EMINENT-ICH):
 a randomized controlled trial

Study ID Not yet applicable

The Sponsor Prof. Dr. med. Raphael Guzman has approved the protocol version **3.0 (dated 18/07/2024)** and confirm hereby to conduct the study according to the protocol, current version of the World Medical Association Declaration of Helsinki, as well as the local legally applicable requirements. This protocol was written in accordance with the SPIRIT guidelines and the SPIRIT-PRO Extension[1, 2].

Sponsor:

Name: Prof. Dr. med. Raphael Guzman

Date: 08.08.2024 | 23:22 MESZ

Signature:

Principal Investigator Basel:

Name: Prof. Dr. med. Jehuda Soleman

Date: 27.07.2024 | 22:25 MESZ

Signature:

Sub-Investigator:

Name: Prof. Dr. med. Urs Fischer

Date: 27.07.2024 | 09:32 PDT

Signature:

Sub-Investigator:

Name: Dr. med. Tim Hallenberger

Date: 27.07.2024 | 17:07 MESZ

Signature:

Local Principal Investigator at study site:

In multicenter studies, this page must individually be signed by all participating Local Principal Investigators.

SITE: University Hospital Bern, Department of Neurosurgery
Freiburgstrasse 16, 3010 Bern

Principal Investigator: *Prof. Dr. med. Andreas Raabe*

Date: 05.08.2024 | 13:24 MESZ

Signature: _____

DocuSigned by:
Prof. Dr. med. Andreas Raabe
CECA2C25CB2D493...

SITE: University Hospital Zurich, Department of Neurosurgery
Frauenklinikstrasse 10, 8091 Zürich

Principal Investigator: *Dr. med. Dr. sc. med. Kevin Akeret*

Date: 28.07.2024 | 00:21 CEST

Signature: _____

Signed by:
Kevin Akeret
79D7BF1D687C48D...

SITE: Kantonsspital St. Gallen, Department of Neurosurgery
Rorschacherstrasse 95, Haus 4, 9007 St. Gallen

Principal Investigator: *PD Dr. med. Dr. sc. nat. Isabel Hostettler*

Date: 27.07.2024 | 17:49 MESZ

Signature: _____

Signiert von:
PD Dr. Isabel Hostettler
487E5161E4524C6...

SITE: Kantonsspital Lucerne, Department of Neurosurgery
Spitalstrasse, Haus 31, 6000 Luzern

Principal Investigator: *Prof. Dr. med. Ulf Schneider*

Date: 29.07.2024 | 00:07 MESZ

Signature: _____

Signiert von:
Ulf Schneider
9B5D2C2F971946D...

SITE: Hôpitaux Universitaires Genève, Department of Neurosurgery
Rue Gabrielle-Perret-Gentil 4, 1205 Geneva

Principal Investigator: *Prof. Dr. med. Philippe Bijlenga*

Date: 27.07.2024 | 18:59 CEST

Signature: _____

Signed by:
Prof. Philippe Bijlenga
61A823B48359426...

SITE: Kantonsspital Winterthur, Department of Neurosurgery
 Brunngasse 30, 8400 Winterthur

Principal Investigator: *Prof. Dr. med. Alex Alfieri*

Date: _____
 27.07.2024 | 09:32 PDT

Signature: _____
 DocuSigned by:
Alex Alfieri
 36121247A44E46F...

SITE: Opedale Regionale di Lugano Civico, Department of Neurosurgery
 Via Tesserete 46, 6900 Lugano

Principal Investigator: *Dr. med. Andrea Cardia*

Date: _____
 12.08.2024 | 09:32 CEST

Signature: _____
 Firmato da:
PD Dr. Andrea Cardia
 8CF60A641D8943D

SITE: Hôpital du Valais - Centre Hospitalier du Valais Romand, Department of Neurosurgery
 Avenue du Grand-Champsec 80, case postale 736, 1950 Sion

Principal Investigator: *PD Dr. med. Dr. sc. nat. Jean-Yves Fournier*

Date: _____
 08.08.2024 | 12:52 CEST

Signature: _____
 Signé par :
PD Dr. Jean-Yves Fournier
 84E6D8A14E3B42E...

SITE : Centre Hospitalier Universitaire vaudois, Department of Neurosurgery,
 Rue du Bugnon 21, 1011 Lausanne

Principal Investigator: *PD Dr. med. Mahmoud Messerer*

Date: _____
 28.07.2024 | 07:52 CEST

Signature: _____
 Signé par :

 4A8F664E6FA9416...

SITE : Kantonsspital Graubünden, Neurochirurgie,
 Loestrasse 170, 7000 Chur

Principal Investigator: *PD Dr. med. Christian Zweifel*

Date: _____
 05.08.2024 | 19:05 MESZ

Signature: _____
 Signiert von:
PD Dr. Christian Zweifel
 15BA7969F57345B...



SITE : Hirslanden Klinik Zürich, Klinik für Neurochirurgie,
Witellikerstrasse 40, 8032 Zürich

Principal Investigator: *Prof. Dr. med. Javier Fandino*

28.07.2024 | 10:45 MESZ

Date: _____

Signature: _____


Signiert von:

0FA282E2B1B649B...

TABLE OF CONTENTS

TABLE OF CONTENTS	5
GLOSSARY OF ABBREVIATIONS	7
1 STUDY SYNOPSIS	9
2 BACKGROUND AND RATIONALE	17
2.1 Explanation for the choice of comparator	18
2.2 Benefits and Risks	18
2.3 Justification of choice of the study population	18
3 STUDY OBJECTIVES AND DESIGN	19
3.1 Hypothesis, primary and secondary objectives	19
3.2 Primary and secondary outcomes	19
3.3 Study design	21
3.3.1 Potential problems associated with the trial desing	21
3.3.2 Methods of minimising bias	21
3.3.3 Randomisation	21
3.3.4 Blinding and Unblinding procedures (Code Break)	22
3.4 Study intervention	22
3.4.1 Intervention group	22
3.4.2 Control group	23
4 STUDY POPULATION AND STUDY PROCEDURES	24
4.1 Inclusion and exclusion criteria, justification of study population	24
4.1.1 Rationale for the inclusion of vulnerable patients	25
4.2 Recruitment, screening and informed consent procedure	25
4.3 Study procedures	26
4.3.1 V1: Study inclusion, baseline assessment and treatment: up to 24 hours after symptom onset	27
4.3.2 V2: Day 1 assessment: 24 ± 6 hours after start of treatment	27
4.3.3 V3: Day 3 assessment: 72 ± 12 hours after treatment	27
4.3.4 V4: Day 7 assessment: 7±1 days after treatment or at hospital discharge	27
4.3.5 V5: Month 3 assessment: 3 months ± 14 days after treatment	27
4.3.6 V6: Month 6 assessment: 6 months ± 7 weeks after treatment	27
4.3.7 V7: 4.3.7V7: Month 12 assessment: 12 months ± 12 weeks after treatment	27
4.3.8 Additional material, storage, cocomitant care as well as methods and tests used for sample collection and analysis	29
4.3.8.1 Imaging analysis	29
4.3.8.2 Questionnaires	29
4.3.8.3 Biomarker analysis	29
4.3.8.4 Concomitant care	30
4.3.8.5 Medical reversal of oral anticoagulation	30
4.3.9 Expected biases to the study and measures taken to reduce them	31
4.4 Withdrawal and discontinuation	31

5	STATISTICS AND METHODOLOGY	31
5.1.	Statistical analysis plan and sample size calculation	31
5.1.1	Hypothesis	31
5.1.2	Sample size estimation	32
5.1.2.1	Derivation of assumptions for analysis of power	32
5.1.2.2	Bayesian Sequential analysis	32
5.1.2.3	Bayesian logistic regression and moment priors	33
5.1.2.4	Stopping rule	33
5.1.2.5	Sample size analysis results	33
5.1.2.6	Conclusion of sample size estimation	34
5.1.3	Planned statistical methods	35
5.1.4	Interim analysis	35
5.1.5	Stratification for outcome analysis	35
5.1.6	Deviations from statistical analysis plan	35
5.2.	Handling of missing data and drop-outs	35
6	REGULATORY ASPECTS AND SAFETY	36
6.1	Local regulations / Declaration of Helsinki	36
6.2	(Serious) Adverse Events and notification of safety and protective measures	36
6.3	(Periodic) safety reporting	37
6.4	Radiation	37
6.5	Pregnancy	37
6.6	Amendments	37
6.7	(Premature) termination of study	38
6.8	Insurance	38
7	FURTHER ASPECTS	38
7.1	Overall ethical considerations	38
7.2	Risk-benefit assessment	39
7.3	Patient and Public involvement	39
8	QUALITY CONTROL AND DATA PROTECTION	39
8.1	Quality measures	39
8.2	Data recording and source data	40
8.2.1	Data recording	40
8.2.2	Source data	40
8.3	Confidentiality and coding	41
8.4	Retention and destruction of study data and biological material	41
8.4.1	Dissemination of study results	42
8.4.2	Reproducibility	42
9	MONITORING AND REGISTRATION	43
10.	FUNDING / PUBLICATION / DECLARATION OF INTEREST	44
10.1	Funding	44
10.2	Publication	44
10.3	Declaration of interest	45
11.	REFERENCES	45
	Appendix 1: Schedule of assessments	49
	Appendix 2: Patient and Public Involvement Plan	50
	Appendix 3 – Patient satisfaction Questionnaire	54
	Appendix 4 - Standardized telephone assessment for the primary outcome	56

GLOSSARY OF ABBREVIATIONS

<i>AE</i>	<i>Adverse Event</i>
<i>ASR/DSUR</i>	<i>Annual Safety Report / Development Safety Report</i>
<i>BASEC</i>	<i>Business Administration System for Ethical Committees</i>
<i>BMT</i>	<i>best medical treatment</i>
<i>CC</i>	<i>Conventional craniotomy</i>
<i>cCT</i>	<i>cranial computed tomography</i>
<i>ClinO</i>	<i>Ordinance on Clinical Trials in Human Research (in German: KlinV, in French: OClin, in Italian: OSRUm)</i>
<i>CRF</i>	<i>Case Report Form</i>
<i>CTCAE</i>	<i>Common Terminology Criteria for Adverse Events</i>
<i>DOAC</i>	<i>direct oral anticoagulants</i>
<i>eCRF</i>	<i>electronic Case Report Form</i>
<i>EDC</i>	<i>electronic data capture</i>
<i>ES</i>	<i>Endoscopic surgery</i>
<i>FADP</i>	<i>Federal Act on Data Protection (in German: DSG, in French: LPD, in Italian: LPD)</i>
<i>FOPH</i>	<i>Federal Office of Public Health</i>
<i>GCP</i>	<i>Good Clinical Practice</i>
<i>GCS</i>	<i>Glasgow Coma Scale</i>
<i>CDMS</i>	<i>Clinical Data Management System</i>
<i>GFAP</i>	<i>Glial Fibrillary Acidic Protein</i>
<i>HRA</i>	<i>Human Research Act (in German: HFG, in French: LRH, in Italian: LRUm)</i>
<i>ICH</i>	<i>International Conference on Harmonisation</i>
<i>ICU</i>	<i>intensive care unit</i>
<i>IL</i>	<i>Interleukin</i>
<i>ISF</i>	<i>investigator site file</i>
<i>MIPS</i>	<i>minimally invasive puncture surgery</i>
<i>MIS</i>	<i>Minimally invasive surgery</i>
<i>MOCA</i>	<i>Montreal Cognitive Assessment</i>
<i>MRI</i>	<i>magnet resonance imaging</i>
<i>mRS</i>	<i>modified Rankin Scale</i>
<i>NfL</i>	<i>the light-chain neurofilament subunit</i>
<i>NIHSS</i>	<i>National Institute of Health Stroke Scale</i>
<i>NOAK</i>	<i>new oral anticoagulants</i>
<i>OAC</i>	<i>Oral anticoagulants</i>
<i>PPI</i>	<i>Patient and Public Involvement</i>
<i>RR</i>	<i>Relative Risk</i>
<i>S100B</i>	<i>S100 calcium-binding protein B</i>
<i>SA</i>	<i>Stereotactic aspiration</i>
<i>SAE</i>	<i>Serious Adverse Event</i>
<i>SIMOA</i>	<i>single-molecule array</i>
<i>SIV</i>	<i>site initiation visit</i>



SSICH
VKA

spontaneous supratentorial intracerebral haemorrhage
Vitamin K antagonists

1 STUDY SYNOPSIS

Sponsor / Sponsor-Investigator	Prof. Dr. med. Raphael Guzman Chair, Head of Vascular and Pediatric Neurosurgery Department of Neurosurgery, University Hospital Basel Spitalstrasse 21, 4031 Basel Raphael.guzman@usb.ch
Study Title	Early minimally invasive image guided endoscopic evacuation of intracerebral haemorrhage (EMINENT-ICH): a prospective randomized controlled trial
Short Title / Study ID	EMINENT-ICH EKNZ 2022-02216
Protocol Version and Date	Version 3.0 (dated 18/07/2024)
Study Registration	SNCTP and Clinicaltrials.gov (NCT05681988)
Study Category and Rationale	B – Inclusion of vulnerable patients and more than minimal risk due to the underlying disease
Background and Rationale	Spontaneous supratentorial intracerebral haemorrhage (SSICH) is the second most common form of stroke and accounts for approximately 2500 cases in Switzerland annually. The prognosis is very poor with nearly half of the patients dying within one year after haemorrhage. Treatment options for SSICH remain ambiguous and consist of either the current gold standard, best medical treatment, or surgical hematoma evacuation. Neither the best medical treatment nor the established surgical mainstay (conventional craniotomy) have shown relevant improvement of survival or functional outcome rates. We therefore propose a minimal invasive approach with early image-guided endoscopic surgery conducted within 24 hours. Endoscopic surgery was shown to be safe and effective, however large trials analyzing the benefits of endoscopic surgery are lacking. We therefore propose, that an earlier, more complete and more rapid hematoma evacuation will improve the functional outcome and mortality rates in these patients.
Risk / Benefit Assessment	This study carries relevant risk of death and disability for the included patients due to the underlying disease of SSICH, however if left untreated, outcome may be even worse with a 30-day mortality up to 45% reaching to 54% at one year. The mortality rates however can be attributed almost exclusively to the underlying disease rather than the procedure. Since this is a surgical procedure, risks like bleeding, wound infections, surgical site infection, and complications related to anaesthesiologic procedures may occur. Furthermore, the procedure might, in extremely rare cases, lead to the death of the participant. Also, due to the location of SSICH, important brain structures have to be passed to access the hematoma cavity and, despite all efforts to conserve them, might be damaged. Overall, we acknowledge the possible risk accompanying the proposed surgical method, but it is our opinion that compared with the medical standard of care for SSICH alone or no treatment at all, these risks are acceptable and fairly balanced with the prospect of potential better survival and less morbidity as well as better functional outcome through the proposed surgical method.
Objective(s)	The primary objective of this two, armed, open-labelled, multi centre randomised controlled trial is to show superiority of early minimally invasive image-guided hematoma evacuation additionally to BMT compared to BMT alone in functional outcome rates at 6 months in patients with SSICH. Secondary objectives are: <ul style="list-style-type: none"> to show superior survival rates of patients in the ES arm to study patient reported quality of life after treatment for SSICH at different time points (3 and 6 months after intervention) to study patient satisfaction with the outcome after treatment for SSICH at different time points (3 months and 6 months after intervention)

	<ul style="list-style-type: none"> to study cognitive outcome in patients after treatment for SSICH at different time points (3 months and 6 months after intervention) to study the morbidity rates of patients in both treatment arms to study the efficacy of ES in reducing the hematoma volume to study the change in focal neurological deficits exhibited by the patients after treatment. to study the temporal evolution of serum biomarkers (Neurofilament light-chain subunit (NfL), Glial Fibrillary Acidic Protein (GFAP), S100 calcium-binding protein B (S100B), IL-1α and β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70 and TNF-α) and their change in relation to early hematoma ES.
<p>Endpoint(s)</p>	<p>Primary outcome:</p> <ul style="list-style-type: none"> Good functional outcome 6 months after treatment, measured by the mRS. Good functional outcome is defined as a mRS of ≤ 3 points and will be assessed as binary outcome (yes/no, final value) at 6 months (blinded) after treatment. The cut-off for good functional outcome is chosen at a mRS score of 3 points, as this reflects the turning point for a patient being able to live a partially self-dependent life or to live a severely disabled life. In this context, a mRS score of 3 points reflects the ability to walk unassisted and care for one's own bodily needs despite being moderately dependent on assistance, while a mRS score of 4 points describes a patient who is not able to walk anymore and needs assistance with all daily activities and thus marks a severe loss of patient autonomy. <p>Secondary outcomes:</p> <ul style="list-style-type: none"> The mortality rate as measured by death of a participant (binary outcome (yes/no), final value) at 6 and 12 months after intervention. Patient reported outcome measures at 3 and 6 months after intervention, those being: <ul style="list-style-type: none"> Patient and caregiver quality of life as assessed by the PROMIS® questionnaire (continuous variable, final value) Patient Satisfaction as assessed by a short survey (Appendix 2) on a scale of 1-5 (continuous variable, final value) Patient cognitive outcome as assessed by the MOCA® Test (continuous variable, final value) The morbidity rate, meaning occurrence of: <ul style="list-style-type: none"> Ischemic stroke Recurrent SSICH (defined as any radiologically confirmed increase in hematoma volume postoperative/follow-up in the same hematoma cavity that is either asymptomatic or associated with a worsening of the focal-neurological deficit by ≥ 4 points on the NIHSS and/or a decrease in consciousness by ≥ 2 points on the GCS occurring within 30 days after treatment onset) Epileptic seizures requiring antiepileptic treatment Surgical site infection (intervention group only) Any need for open neurosurgical procedures Life-threatening infections (i.e. pneumonia) Any other not defined complication that prolongs the hospital stay and/or leads to further treatment not envisaged in the original treatment plan. <p>The occurrence of any of these events 6 and 12 months after intervention (binary variable (occurrence/no occurrence), final value, proportion).</p> <ul style="list-style-type: none"> The change of focal neurological deficit measured by the NIHSS, from baseline to 6 months after intervention as a continuous variable (continuous variable, change from baseline). The change of disability measured by the mRS, from baseline to 6 and 12 months after intervention as a continuous variable (change from baseline, so called mRS shift analysis).

	<ul style="list-style-type: none"> The time to intervention, defined as the period from symptom onset/last seen well to start of surgery (start surgical measures, i.e. positioning of patient) or start of medical treatment (admission of first treatment of BMT) (continuous variable, time to event). The temporal evolution of serum levels of the prespecified biomarkers as continuous variable from start to 6 months after intervention (continuous variable, change from baseline). The total time spent on the intensive care unit (ICU)/stroke unit as a continuous variable from the first admission to the ICU/stroke unit to discharge from ICU/stroke unit at 7 days/discharge after intervention (continuous variable, final value). The total time spent in intubation measured in minutes from the start of intubation to extubation as specified in the anesthesiology report at 7 days/discharge after intervention (continuous variable, final value). <p>Outcomes/Measurements applying to the intervention group only:</p> <ul style="list-style-type: none"> The proportion of satisfactory hematoma volume reduction rate (goal $\leq 15\%$ of its initial volume). The hematoma volume will be measured on serial cranial computer tomography (cCT) and the difference between the volume of the cCT used for surgery and the cCT directly after surgery will be calculated. The hematoma volume on the pre-operative cCT will be calculated using the $(A * B * C)/2$ method during screening and secondarily validated using the volumetric function of the navigation software. Hematoma on directly postoperative images will be calculated using the volumetric function of the navigation software. The hematoma volume reduction rate will be a binary variable (achieved reduction $< 15\%$/did not achieve reduction $< 15\%$, final value). The relative (percentage) reduction or increase of hematoma volume from baseline admission cCT to postoperative cCT directly after surgery as a continuous variable (final value).
Study Design	This is a national multi-centre, two-arm, open labelled randomised controlled trial within the stroke units and stroke centres of the Swiss stroke registry in a superiority fashion.
Statistical Considerations	<p>The primary analyses are performed following the intention-to-treat principle. Additionally, per-protocol analysis will be performed for sensitivity analysis. We study the ratio of positive outcomes in both study arms by performing a Bayesian logistic regression test after every 40 additional patients, using the method described by Bartos and Wagenmaker et al.. Data collection (and the periodical analysis of these data) will continue until a Bayes Factor of 10 (or 1/10) is achieved. The odds ratio and its 95% credible interval will be reported.</p> <p>Secondary analysis is performed on the secondary outcomes. For continuous variables, a Bayesian regression with normal error term is used, for time-to-event outcomes Bayesian cox-regression is used, and for binary variables Bayesian logistic regression is used adjusted for covariates. Statistical analysis is performed with R version 4.2.1 or higher (R core Team, 2022).</p> <p>In parallel to the first Bayesian analysis for the first 40 patients per study arm, we will perform a frequentist logistic regression. In the ES arm, a number of explorative analyses are performed, studying the relation between hematoma location, hematoma size, and treatment outcome. In particular, for parameters measured over time, figures are created illustrating the development over time at both the patient level and group level.</p>
Inclusion- / Exclusion Criteria	<p>Inclusion criteria:</p> <ul style="list-style-type: none"> Patient age ≥ 18 and < 85 Spontaneous supratentorial intracerebral hemorrhage (SSICH), defined as the sudden occurrence of bleeding into the lobar parenchyma and/or into the basal ganglia and/or thalamus that may extend into the ventricles confirmed by imaging. SSICH volume ≥ 20 mL < 100 mL (measured using the formula $\frac{A * B * C}{2}$) A focal neurological deficit consisting of either:

	<ul style="list-style-type: none"> ○ clinically relevant hemiparesis (≥ 4 motor points on the NIHSS for facial palsy, motoric upper and lower extremities combined) ○ clinically relevant motor or sensory aphasia (≥ 2 points on the NIHSS) ○ clinically relevant hemi-inattention (formerly neglect, 2 points on the NIHSS) ○ decreased level of consciousness (GCS≤ 13) <ul style="list-style-type: none"> • Presenting GCS 5 – 15 (in intubated patients GCS assessment will be performed after Rutledge et al. or if impossible, the last pre-intubation GCS will be used) • Endoscopic hematoma evacuation can be initiated within 24 hours after the patient was last seen well/symptom onset • Informed consent of patient (only for patients able to consent) <p>Exclusion criteria:</p> <ul style="list-style-type: none"> • SSICH due to known or suspected structural abnormality in the brain (e.g. vascular malformation, aneurysm, AVM, brain tumor) and/or brain trauma and/or hemorrhagic conversion of an ischemic infarction • Multiple simultaneous intracranial hemorrhages (e.g. multifocal ICH, cSDH, aSDH, SAH) • Infratentorial hemorrhage or midbrain extension/involvement of the hemorrhage • Coagulation disorder (including anticoagulation) with an INR of >1.5 which cannot be pharmacologically reverted until the planned time of evacuation • Positive history of current pregnancy or breast-feeding • Relevant disability prior to SSICH (mRS >2) Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 180 days (e.g. bilateral fixed dilated pupils)
<p>Number of Participants with Rationale</p>	<p>Based on the to-date available literature, our own meta-analysis and the data of 2020-2022 derived from the Swiss stroke registry we assume a favorable outcome around 50% for patients treated with BMT, while we anticipate a positive risk ratio of 1.6 (equaling to an OR of 4) towards favorable outcome for ES compared to BMT. Based on these assumptions, we explored sample sizes needed for achieving “compelling evidence”, as described by Schönbrodt & Wagenmaker.</p> <p>Systematic reviews as well as data analyzed from the Swiss Stroke Registry over the last 2 years suggests that a plausible assumption for the proportion of positive outcomes in the control arm is 50% (0.5). Based on our calculations after collecting data of 70 patients per study arm, about 90% of trials will have achieved a BF of 10, being the “Bayesian equivalent” to a power of 90%. Note that 50% of the simulated trials already achieve this level of evidence after the 40th hypothetical patient (per arm). Further, based on these calculations, it is very unlikely that the trial would take more than 100 patients per arm. Based on these results we assume that we will likely be able to stop collecting data before reaching 80 patients per arm (total of 160 patients) to reach a BF of 10.</p>
<p>Study Intervention</p>	<p>Early minimally invasive image guided endoscopic hematoma evacuation as an add-on therapy to BMT performed within 24 hours after SSICH symptom onset.</p>
<p>Control Intervention</p>	<p>Best medical treatment i.e., active blood pressure control, seizure prophylaxis and care as according to the current guidelines.</p>
<p>Study procedures</p>	<p>7 Visits in total, 4 of them during hospital stay, 3 of them as follow-up, 2 of which as visits within the clinical routine and one telephone interview. Aside from visit 7, each visit consists of assessing GCS, mRS and NIHSS, three visits include CT scans (before intervention, directly postoperative and during follow up) and blood sampling (before intervention, postoperative and during follow up). Two visits include assessing patient satisfaction and cognition, and two visits include patient quality of life assessments.</p>
<p>Study Duration and Schedule</p>	<p>Estimated duration for the main investigational plan is estimated to last 5 years.</p> <p>Planned 01/2024 of First-Participant-In Planned 09/2028 of Last-Participant-Out</p>
<p>Investigator(s)</p>	<p>Principal Investigator: Prof. Dr. med. Jehuda Soleman Senior Neurosurgeon, Head of Clinical Research</p>

	<p>Department of Neurosurgery, University Hospital Basel Spitalstrasse 21, 4031 Basel Jehuda.soleman@usb.ch</p> <p>Sub-Investigators: Prof. Dr. med. Urs Fischer Chair of Neurology, Head of the Department of Neurology Department of Neurology, University Hospital Bern Rosenbühlgasse 25, 3010 Bern urs.fischer@insel.ch</p> <p>Dr. med. Tim Hallenberger MD PhD Candidate Department of Neurosurgery, University Hospital Basel Spitalstrasse 21, 4031 Basel tim.hallenberger@usb.ch</p> <p>Prof. Dr. med. Ulf Schneider Chair of Neurosurgery Kantonsspital Luzern Ulf.schneider@luks.ch</p> <p>Prof. Dr. med. Andreas Raabe Chair of Neurosurgery University Hospital Bern Andreas.raabe@insel.ch</p> <p>Prof. Dr. med. Philippe Bijlenga Senior Attending Neurosurgeon Hôpitaux Universitaire Genève HUG Philippe.bijlenga@hcuge.ch</p> <p>Dr. med. Julien Haemmerli Junior attending Neurosurgeon Hôpitaux Universitaire Genève HUG Julien.haemmerli@hcuge.ch</p> <p>Univ.-Prof. Dr. med. Alex Alfieri Chair of Neurosurgery Kantonsspital Winterthur Alex.alfieri@ksw.ch</p> <p>PD Dr. med. Dr. sc. nat. Isabel Hostettler Senior Attending Neurosurgeon Kantonsspital St. Gallen Isabel.hostettler@kssg.ch</p> <p>Dr. med. Dr. sc. med. Kevin Akeret Attending Neurosurgeon University Hospital Zürich Kevin.akeret@usz.ch</p> <p>Dr. Andrea Cardia Chair of Neurosurgery Ospedale Regionale di Lugano Civico Andrea.cardia@eoc.ch</p> <p>Dr. med. Davide Milani</p>
--	---

	<p>Attending Neurosurgeon Ospedale Regionale di Lugano Civico Davide.milani@eoc.ch</p> <p>PD Dr. med. Dr. sc. med. Jean-Yves Fournier Chair of Neurosurgery Hôpital du Valais – Centre Hospitalier du Valais Romand Jean-yves.fournier@hopitalvs.ch</p> <p>PD Dr. med. Mahmoud Messerer Senior Attending Neurosurgeon Centre Hospitalier Universitaire Vaudoise Mahmoud.messerer@chuv.ch</p> <p>PD Dr. med. Christian Zweifel Chair of Neurosurgery Kantonsspital Graubünden Christian.zweifel@ksgr.ch</p> <p>Prof. Dr. med. Javier Fandino Chair of Neurosurgery Klinik Hirslanden Zürich Javier.fandino@hirslanden.ch</p> <p>Prof. Dr. med. Niels Peters Chair of Neurology Klinik Hirslanden Zürich Niels.peters@hirslanden.ch</p>
<p>Study Center(s)</p>	<p>Department of Neurosurgery University Hospital Basel Spitalstrasse 21 CH-4031 Basel Switzerland</p> <p>Department of Neurosurgery Kantonsspital St. Gallen Rorschacherstrasse 95, Haus 4 9007 St. Gallen Switzerland</p> <p>Department of Neurosurgery Kantonsspital Luzern Spitalstrasse, Haus 31 6000 Luzern Switzerland</p> <p>Department of Neurosurgery University Hospital Bern Freiburgstrasse 16 3010 Bern Switzerland</p> <p>Department of Neurosurgery Hôpitaux Universitaire Genève HUG Rue Gabrielle-Perret-Gentil 4 1205 Geneva Switzerland</p>

	<p>Department of Neurosurgery Kantonsspital Winterthur Brunngasse 30 8400 Winterthur Switzerland</p> <p>Department of Neurosurgery University Hospital Zurich Frauenklinikstrasse 10 8091 Zürich Switzerland</p> <p>Department of Neurosurgery Opedale Regionale di Lugano Civico Via Tesserete 46 6900 Lugano Switzerland</p> <p>Department of Neurosurgery Hopital du Valais – Centre Hospitalier du Valais Romand Avenue du Grand-Champsec 80 1950 Sion</p> <p>Department of Neurosurgery Centre Hospitalier Universitaire Vaudois Rue du Bugnon 21 1011 Lausanne</p> <p>Neurosurgical Unit Kantonsspital Graubünden Loestrasse 170 7000 Chur</p> <p>Department of Neurosurgery Klinik Hirslanden Zürich Wittelikerstrasse 40 8032 Zürich</p>
<p>Data privacy</p>	<p>A unique patient identifier (i.e., patients study ID) will be used to identify patients and a password protected list will be maintained for traceability. The patient ID is generated when the patient is enrolled in the CDMS secuTrial® by consecutive automatic numbering (i.e., XXX-NNN with XXX referring to the center and NNN to a tree digit number). Only the PI or delegated study personnel at the respective site will have access to the encoding key. Enrolment and screening logs will be filed to ensure traceability. The Principal Investigator and, if applicable, delegates at the sites will be authorized to do eCRF entries. The CDMS is accessible via a standard browser on devices with internet connection. Password protection and user-right management ensures that only authorized study investigators, monitors, data managers and local authorities (if necessary) will have access to the data during and after the study. An audit trail will maintain a record of initial entries and any changes made; time and date of entry; and username of person authorizing entry or change. Participant’s identification logs will be stored as a password protected word files and saved on protected servers of the respective study sites. On CRFs and other study specific documents, participants are only identified by the patient’s study ID derived by secuTrial®. Completed paper CRFs will be kept locked in a drawer at the respective study sites with access only to a very limited number of study team members and regularly send to the main center (Basel) for data entry. ECRFs will be secured in secuTrial®, only accessible by the Sponsor, PI, and the study teams at the respective sites. The Investigators and the Sponsor endorse responsibility, that nobody</p>

	<p>else will have access to the confidential data and they guarantee protection against dissemination.</p> <p>Biological material in this study (i.e., blood samples) are not identified by participant name but by the patient's study ID. Biological material is stored in an appropriate cooling system in a restricted area only accessible to the authorized personnel and handled under appropriate conditions. Biological material will be discarded after analysis as according to the site's regulations for biological waste. All study data, except blood samples, will be archived for a minimum of 10 years after study termination or premature termination of the clinical trial.</p>
<p>Ethical consideration</p>	<p>SSICH is a devastating disease affecting 2500 patients per year in Switzerland. As of today, nearly 60 years into the research of the ideal treatment of SSICH, effective treatment options improving not only mortality but more importantly functional outcome and HRQoL do not exist.</p> <p>With the results of this multi-center, randomized controlled trial, we will generate highly relevant data, which will shape the future management of SSICH and lead to an improved treatment and outcome for patients.</p>
<p>GCP Statement</p>	<p>This study will be conducted in compliance with the protocol, the current version of the Declaration of Helsinki, the ICH-GCP, the HRA as well as other locally relevant legal and regulatory requirements. A clinical trial covered by ClinO Chapter 4 may be conducted in accordance with other rules than ICH-GCP guidelines, provided that such rules are recognised in the specialty in question and the protection of participants and data quality, and security are guaranteed (ClinO Art. 5, Abs 2).</p>

2 BACKGROUND AND RATIONALE

Spontaneous supratentorial intracerebral haemorrhage (SSICH) is the second most common form of stroke, accounting for roughly 9-27% of all strokes and affecting more than 5 million people worldwide annually (approx. 2500 cases in Switzerland annually)[3]. Mortality rates are high with a range of 40-45%[4]. Patients surviving an SSICH mostly have very poor Health Related Quality of Life (HRQoL) and serious neurological deficits resulting in great burdens for them, their relatives and the social system[5-7].

Primary brain injury in SSICH occurs due to intra-axial bleeding causing mass effect and destruction of brain tissue[8]. Secondary mechanisms of brain injury are the local decay of hemoglobin, causing further brain damage due to its toxicity and delayed brain edema[9]. As such, the hematoma volume plays a vital role, as larger hematoma volumes lead to poorer outcome[10].

Treatment options for SSICH aim to stop enlargement of the hematoma volume or aim to evacuate the hematoma volume itself[11]. They consist of either, best medical treatment (a combination of medical blood pressure control, intensive care and prevention of secondary complications) short BMT, considered the current gold standard of treatment, or open surgical hematoma evacuation. Both treatment arms, showed similarly low rates of good functional outcome and survival (Class of Recommendation 2a, Level of Evidence B)[11, 12]. Intensive blood pressure reduction to below 140mmHg showed minimal improvement of functional outcome (OR 0.87, $p=0.04$) and mortality rates (OR 0.75, $p=0.06$)[13, 14].

Surgical treatment options for SSICH can be divided into conventional craniotomy (CC) and minimally invasive surgery (MIS), including endoscopic surgery (ES) and stereotactic aspiration (SA)[11, 15]. The Surgical Treatment for Intracerebral Haemorrhage (STICH) I and II trials, failed to show significant superiority of open surgical removal of SSICH with CC compared to BMT for improved functional outcomes or mortality[16, 17].

MIS on the other hand seems to be a promising alternative to BMT and CC. Recent systematic reviews/meta-analysis suggested that MIS leads to markedly improved survival and favorable outcome rates compared to BMT, yet the most promising MIS technique remains elusive[18, 19].

The MISTIE (minimally invasive surgery plus rt-PA [alteplase] in intracerebral haemorrhage evacuation) I, II and III trials assessed the potential superiority of minimally invasive hematoma removal using SA (stereotactic insertion of a catheter into the hematoma cavity, repetitive irrigation of the blood clot using thrombolytic agents and subsequent hematoma drainage) compared to BMT[20-22]. MISTIE II demonstrated efficacy in reducing hematoma volume, clinical safety, and feasibility. MISTIE III evaluated good functional outcome after 1 year (modified Rankin Scale (mRS) ≤ 3 points) showing no significant difference between SA and BMT, while SA significantly reduced the all-cause mortality throughout the study period[21]. Recently, ES emerged as a safe and effective treatment option of SSICH[18, 23-26]. Meta-analysis showed decreasing mortality and higher favorable outcome rates after ES, compared to BMT. Further, compared to SA, more rapid hematoma evacuation and compared to CC lower morbidity rates were seen[18, 23, 24, 26]. We confirmed these results in our own meta-analysis, where we compared ES to BMT as a single comparator, which showed a significantly improved favorable outcome rate and an improved survival rate ($p=0.02$ and 0.01 respectively). Despite these promising findings, to date, large randomized controlled trials assessing the superiority of ES over BMT in SSICH are lacking[12, 27]. In the MISTIE III trial, evacuation of half the hematoma volume took two days on average with a median time between bleeding onset and randomization of 47 hours. Additionally, the optimal timing to hematoma evacuation remains elusive. A subgroup analysis of MISTIE III showed that patients receiving treatment within 36 hours after symptom onset profited more than those with later treatment onset ($>36h$)[22]. Likewise, a meta-analysis reports a 2.8 times greater likelihood of achieving functional independence if patients received hematoma evacuation within 24 hours after symptom onset[23]. This was confirmed by Kellner et al., stating that delayed treatment onset reduces the rate of favorable outcome by 5% per hour lost[28]. These findings suggest that early surgical hematoma evacuation is vital for the improvement of functional outcome and survival in SSICH.

Ultra-early hematoma evacuation (<7h) however, was associated with higher mortality rates and therefore, it seems that the optimal treatment window lies within the first 6-24 hours after bleeding onset[29, 30]. To this date, large randomized controlled trials analyzing this specific treatment window with ES are lacking.

Lastly, patient reported outcomes measures (PROMs) and cognitive outcomes in ES compared to BMT are currently underreported (if reported at all)[31]. Within the frame of the EMINENT-ICH trial these aspects will be evaluated in a standardized fashion.

Based on the pathophysiological considerations, the current literature and our own data, we are convinced, that evacuating SSICH in a minimal invasive endoscopic fashion, within 6-24 hours and achieving a fast and significant reduction of hematoma volume will result in superiority of good functional outcome and lower morbidity rates compared to BMT.

The present study aims to demonstrate efficacy of ES as add on therapy to BMT (henceforth simply referred to as ES) versus BMT alone in improving functional outcome and reducing death and dependency among patients with SSICH in a randomised controlled fashion. We further aim to contribute to the ongoing understanding of secondary neuronal damage involved in SSICH and their response to early hematoma evacuation, which leads to novel insights and possibly novel treatment modalities.

2.1 Explanation for the choice of comparator

Best medical treatment (a combination of medical blood pressure control, intensive care and prevention of secondary complications)[12], which is considered the gold standard treatment of SSICH, acts as comparator in this randomized controlled trial. Therefore, we will be comparing ES with the standard of care (BMT) applied in all stroke centres and stroke units in Switzerland.

2.2 Benefits and Risks

This study carries relevant risk of death and disability for the included patients which is almost exclusively accountable to the underlying disease of SSICH, however if SSICH is left untreated, outcome may be even worse with a 30-day mortality up to 45% reaching to 54% at one year[32]. Since this study includes a surgical procedure, risks like bleeding, wound infections, surgical site infection, and complications related to anaesthesiologic procedures may occur. Furthermore, the procedure might, in extremely rare cases, lead to the death of the participant. Due to the location of SSICH, important brain structures might be damaged by accessing the hematoma cavity despite all efforts to conserve them.

Despite this, when compared to the potential damage inflicted by untreated SSICH, these complications are acceptable. If our hypothesis is correct, then the participants might benefit in form of better survival and functional outcome rates from the proposed intervention.

For further details, please refer to section 7.2 “Risk-Benefit Assessment”.

2.3 Justification of choice of the study population

The study population will include patients with spontaneous supratentorial intracerebral haemorrhage (SSICH). In accordance with our power analysis, we plan to enrol a total of 200 patients (100 patients in the intervention group, 100 patients in the control group). Vulnerable patients (i.e. not able to consent due to impaired consciousness) will be enrolled in this study. Since this study is partially based in an emergency setting, time is of vital importance. If unresponsive participants or participants incapable of judgement show signs that they are unwilling to participate in this study, then they will be excluded from this study. In case a patient is not able to consent, an independent physician will be asked to confirm that the interests of the patient are preserved.

For further details, please refer to sections 4.1 “Inclusion and Exclusion criteria, justification of study population” and 4.2 “Recruitment, screening and informed consent procedure”.

3 STUDY OBJECTIVES AND DESIGN

3.1 Hypothesis, primary and secondary objectives

The **Null hypothesis (H₀)** describes no difference in functional outcome rates of early minimally invasive image-guided endoscopic evacuation additionally to BMT for SSICH compared to BMT alone.

The **Alternative Hypothesis (H₁)** describes a difference (either improved or worsened [two-sided testing]) functional outcome rates of early minimally invasive image guided endoscopic evacuation additionally to BMT for SSICH compared to BMT alone.

The primary objective of this two, armed, open-labelled, multi centre randomised controlled trial is to show superiority of early minimally invasive image-guided hematoma evacuation additionally to BMT compared to BMT alone in functional outcome rates at 6 months in patients with SSICH.

Secondary objectives are:

- to show superior survival rates of patients in the ES arm
- to study patient reported quality of life after treatment for SSICH at different time points (3 and 6 months after intervention)
- to study patient satisfaction with the outcome after treatment for SSICH at different time points (3 months and 6 months after intervention)
- to study cognitive outcome in patients after treatment for SSICH at different time points (3 months and 6 months after intervention)
- to study the morbidity rates of patients in both treatment arms
- to study the efficacy of ES in reducing the hematoma volume
- to study the change in focal neurological deficits exhibited by the patients after treatment.
- to study the temporal evolution of serum biomarkers (Neurofilament light-chain subunit (NfL), Glial Fibrillary Acidic Protein (GFAP), S100 calcium-binding protein B (S100B), IL-1 α and β , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70 and TNF- α) and their change in relation to early hematoma ES.

3.2 Primary and secondary outcomes

Primary outcome:

- Good functional outcome 6 months after treatment, measured by the mRS[33]. Good functional outcome is defined as a mRS of ≤ 3 points and will be assessed as binary outcome (yes/no, final value) at 6 months after treatment. The cut-off for good functional outcome is chosen at a mRS score of 3 points, as this reflects the turning point for a patient being able to live a partially self-dependent life or to live a severely disabled life. In this context, a mRS score of 3 points reflects the ability to walk unassisted and care for one's own bodily needs despite being moderately dependent on assistance, while a mRS score of 4 points describes a patient who is not able to walk anymore and needs assistance with all daily activities and thus marks a severe loss of patient autonomy.

Secondary outcomes:

- The mortality rate as measured by death of a participant (binary outcome (yes/no), final value) at 6 and 12 months after intervention.

- Patient reported outcome measures at 3 and 6 months after intervention, those being:
 - Patient and caregiver quality of life as assessed by the PROMIS® questionnaire (continuous variable, final value)
 - Patient Satisfaction as assessed by a short survey (Appendix 2) on a scale of 1-5 (continuous variable, final value)
 - Patient cognitive outcome as assessed by the MOCA® Test (continuous variable, final value)
- The morbidity rate, meaning occurrence of:
 - Ischemic stroke
 - Recurrent SSICH (defined as any radiologically confirmed increase in hematoma volume postoperative/follow-up in the same hematoma cavity that is either asymptomatic or associated with a worsening of the focal-neurological deficit by ≥ 4 points on the NIHSS and/or a decrease in consciousness by ≥ 2 points on the GCS occurring within 30 days after treatment onset)
 - Epileptic seizures requiring antiepileptic treatment
 - Surgical site infection (intervention group only)
 - Any need for open neurosurgical procedures
 - Life threatening infections (i.e., pneumonia, urinary tract infection)
 - Any other not defined complication that prolongs the hospital stay and/or leads to further treatment not envisaged in the original treatment plan.

The occurrence of any of these events 6 and 12 months after intervention (binary variable (occurrence/no occurrence), final value, proportion).

- The change of focal neurological deficit measured by the NIHSS, from baseline to 6 months after intervention as a continuous variable (continuous variable, change from baseline).
- The change of disability measured by the mRS, from baseline to 6 and 12 months after intervention as a continuous variable (change from baseline, so called mRS shift analysis).
- The time to intervention, defined as the period from symptom onset/last seen well to start of surgery (start surgical measures, i.e., positioning of patient) or start of medical treatment (admission of first treatment of BMT) (continuous variable, time to event).
- The temporal evolution of serum levels of the prespecified biomarkers as continuous variable from start to 6 months after intervention (continuous variable, change from baseline).
- The total time spent on the intensive care unit (ICU)/stroke unit as a continuous variable from the first admission to the ICU/stroke unit to discharge from ICU/stroke unit at 7 days/discharge after intervention (continuous variable, final value).
- The total time spent in intubation measured in minutes from the start of intubation to extubation as specified in the anesthesiology report at 7 days/discharge after intervention (continuous variable, final value).

Outcomes/Measurements applying to the intervention group only:

- The proportion of satisfactory hematoma volume reduction rate (goal $\leq 15\%$ of its initial volume). The hematoma volume will be measured on serial cranial computer tomography (cCT) and the difference between the volume of the cCT used for

surgery and the cCT directly after surgery will be calculated. The hematoma volume on the pre-operative cCT will be calculated using the $(A * B * C)/2$ method during screening and secondarily validated using the volumetric function of the navigation software[34] Hematoma on directly postoperative images will be calculated using the volumetric function of the navigation software. The hematoma volume reduction rate will be a binary variable (achieved reduction<15%/did not achieve reduction<15%, final value).

- The relative (percentage) reduction or increase of hematoma volume from baseline admission cCT to postoperative cCT directly after surgery as a continuous variable (final value).

Additionally, we will collect baseline data of all patients such as age, sex, prior medical history and medication out of the electronic patient file.

Baseline factors acting as confounders and/or effect modifiers potentially influencing the primary and secondary endpoints are: age, existing comorbidities and use of oral anticoagulants (OAC, including Vitamin K Antagonists [VKA], New Oral Anticoagulants [NOAC], Direct Oral Anticoagulants [DOAC]). Correction in the primary outcome analysis will be conducted for; ICH volume, presence of intraventricular haemorrhage, do-not-resuscitate orders, location of haemorrhage and centre.

3.3 Study design

This is a national multi-centre, two-arm, open labelled randomised controlled trial within the stroke units and stroke centres of the Swiss stroke registry in a superiority fashion.

3.3.1 Potential problems associated with the trial desing

As no blinding of the surgeons or the patients is possible, potential bias can occur in this trial. Furthermore, the Hawthorne effect could be observed since the patients are aware of which treatment arm they received. Lastly, enrolment rates can become problematic.

3.3.2 Methods of minimising bias

We plan to enrol a large enough sample to eliminate random error. Randomisation in 1:1 fashion should reduce any selection bias of patients due to the treating physician's expectation and possible confounders are well distributed among the groups. Randomisation will be done using a CDMS (SecuTrial®) by a trained member of the study personnel. All study personnel will be trained and instructed for the study procedures. The primary outcome evaluation is performed by blinded study personnel via telephone interviews, the primary outcome analysis is performed by our blinded trial statistician not involved the treatment plan of the patients. Other forms of reducing bias will be the use of prospective CRF Forms, the use of validated and commonly applied scores (mRS/NIHSS/GCS/PROMIS®/MOCA) for the outcome assessments and blinded laboratory personnel assessing the biomarker results, as the individuals analysing the biomarkers will have no information regarding the treatment plan of the patient. Lastly, regular quality control will take place to ensure that all procedure standards are met. Explorative stratified sub-group analysis accounting for possible confounders mentioned in 3.2 will be conducted. Intention to treat and per protocol analysis will be performed.

3.3.3 Randomisation

Each eligible patient will be allocated to either the early ES or the BMT group in a 1:1 fashion, stratified for centre and with variable block length. This process will take place 1) after enrolment criteria were met, 2) the patient gave his/her consent or, if the patient is not able to consent, an independent physician confirmed that the interests of the patient are preserved and 3) within 24 hours after symptom onset. A trained individual of the study team will implement the randomisation procedure within SecuTrial®. The allocation sequence is programmed in our

CDMS SecuTrial®, which generates random block randomization algorithms of variable length for a randomization in a 1:1 fashion. It will also include a standard minimisation algorithm which will ensure that the treatment groups are balanced. The allocation sequence will be programmed in the CDMS by the data manager and, if necessary, a study-independent statistician. Patient ID and study arm will be generated by the randomization program and disclosed to the treating team electronically. Thus, the treatment allocation is concealed to the study team until randomization is conducted.

3.3.4 Blinding and Unblinding procedures (Code Break)

Since this is a surgical trial, blinding is not possible for primary care providers. However, the laboratory personnel analyzing the biomarkers as well as the statistician will be blinded as these are not directly involved in the patient care or outcome assessment. Laboratory personnel will be blinded to the allocation as only encoded material will be processed where patients are identified by their patient ID, which gives no hint to the allocation. Likewise, the study statistician responsible for the primary analysis will receive a blinded copy of the data sets. Furthermore, we will conduct blinded outcome assessment at 3 and 6-month follow-up through study personnel blinded to the allocation of the patient in form of a standardized telephone assessment (Appendix 4)[35]. This form of assessment is highly comparable with face-to-face evaluation, is short and easy to implement[36].

Since no patient or care provider blinding is possible (due to the study design including a surgical treatment arm), no emergency unblinding is necessary.

3.4 Study intervention

3.4.1 Intervention group

The intervention group will first receive BMT (as described below) upon admission and early minimally invasive image guided endoscopic hematoma evacuation as an add-on therapy to BMT. Surgery will be performed within 6-24 hours after SSICH symptom onset. A detailed standardized presentation of the technique and all critical steps of the surgery including imaging, setup of image guidance and endoscopic equipment, as well as the exact process of aspirating the clot will be provided to all involved surgeons by a proctored workshop. Additionally, we published a technical note describing the technique with a video illustrating the steps of the surgery[37]. All individual parts of the procedure are standard neurosurgical practice. Regular training will be conducted to maintain and improve adherence.

The initial cCT scan will be used for presurgical planning of the neuro-navigation. The entry point and trajectory to the hematoma will be determined on a routine presurgical BrainLab® neuro-navigation planning station (BrainLab®, Munich, Germany) or an equivalent neuro-navigation planning station (e.g. Medtronic Stealth planning station, Fig. 1a). The planned trajectory represents the shortest approach from the surface of the brain to the hematoma, ideally in adequate distance from functional (eloquent) areas of the brain. Surgery will be performed in an emergency operating theatre or a hybrid operation theatre equipped with intraoperative CT (in hybrid OR), neuronavigation, and neuro-endoscopy. Neuro-navigation will be used to mark the skin incision and the exact location of the entry burr hole (Fig. 1b). The burr hole will be drilled and a transparent trocar (ViewSite Brain Access System®, VycorMedical™, U.S.A or equivalent) will be used as a working channel for the endoscope and the suction device (regular suction device, Artemis®, Apollo®, or other suction devices, Fig. 1c and d). The position and progress of the trocar towards the hematoma cavity will be monitored with neuro-navigation. The endoscope (LOTTA® system, Karl Storz Endoscopes, Germany; Minop®, BBraun, Tuttlingen, Germany or equivalent) will be inserted into the trocar and tracked using neuro-navigation. Using the pre-planned trajectory, the hematoma will be entered. Using continuous suction and irrigation, the hematoma will be aspirated and washed out (Fig. 1e). Under visual control using the endoscope, the hematoma cavity will be continuously monitored and active bleeding areas will be irrigated or coagulated using the endoscopic coagulation device and Floseal®. After the hematoma cavity has been cleared, a final inspection under endoscopic visualization will be carried out (Fig. 1f). Thereafter, the wound is closed in standard neurosurgical fashion[37]. Directly after surgery, while

still intubated and sedated, patients will be transferred for a cCT in order to assess adequate hematoma evacuation. In a hybrid OR setting, the cCT will be performed directly in the operating theatre. If hematoma removal is found insufficient by the treating neurosurgeon, the patient will return to the operating theatre for further hematoma aspiration (using the same approach). After surgery patient's will be monitored and cared for in an intensive care/stroke unit. The patient will then be treated, according to the current guidelines for BMT in SSICH[12] (systolic BP <140mmHg, ICU care, controlling seizures and glucose levels).




Figure 1: Steps of the surgery: A) Planning of the access; B) Confirming the entry point; C) The burr-hole access; D) Working with the suction device and the endoscope; E) suction of hematoma; F) completely evacuated hematoma cavity

3.4.2 Control group

The control group will receive the current gold standard treatment for SSICH according to the guidelines (BMT)[12]. This involves strict blood pressure control (SBP<140mmHg), if needed with intravenous or intraarterial blood pressure lowering agents, reversal of anticoagulation if applicable, intensive care surveillance and nursing on a ICU or stroke unit, control of seizures as well as glucose levels as needed and neurointensive monitoring if deemed necessary[12].

4 STUDY POPULATION AND STUDY PROCEDURES

4.1 Inclusion and exclusion criteria, justification of study population

The study population consists of patients with spontaneous supratentorial ICH (SSICH) defined by the following inclusion criteria upon screening. In accordance with our power analysis, we plan to enrol a total of 200 patients (100 patients in the intervention group, 100 patients in the control group). The recruitment procedure is described in 4.2 “recruitment, screening and informed consent procedure”.

Inclusion criteria:

- Patient age ≥ 18 and <85
- Spontaneous supratentorial intracerebral hemorrhage (SSICH), defined as the sudden occurrence of bleeding into the lobar parenchyma and/or into the basal ganglia and/or thalamus that may extend into the ventricles confirmed by imaging
- SSICH volume ≥ 20 mL <100 mL (measured using the formula $\frac{A * B * C}{2}$)
- A focal neurological deficit consisting of either
 - clinically relevant hemiparesis (≥ 4 motor points on the NIHSS for facial palsy, motoric upper and lower extremities combined)
 - clinically relevant motor or sensory aphasia (≥ 2 points on the NIHSS)
 - clinically relevant hemi-inattention (formerly neglect, 2 points on the NIHSS)
 - decreased level of consciousness ($GCS \leq 13$)
- Presenting GCS 5 – 15 (in intubated patients GCS assessment will be performed after Rutledge et al.[38] (Figure 2) or if impossible, the last pre-intubation GCS will be used)
- Endoscopic hematoma evacuation can be initiated within 24 hours after the patient was last seen well/symptom onset
- Informed consent of patient (only for patients able to consent)

Exclusion criteria:

- SSICH due to known or suspected (on CT-A scan) structural abnormality in the brain (e.g. vascular malformation, aneurysm, AVM, brain tumor) and/or brain trauma and/or hemorrhagic conversion of an ischemic infarction
- Multiple simultaneous intracranial hemorrhages (e.g. multifocal ICH, cSDH, aSDH, SAH)
- Infratentorial hemorrhage or midbrain extension/involvement of the hemorrhage
- Coagulation disorder (including anticoagulation) with an INR of >1.5 which cannot be pharmacologically reverted until the planned time of evacuation
- Positive history of current pregnancy or breast-feeding in premenopausal women
- Relevant disability prior to SSICH (mRS >2)

- Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 180 days (e.g., bilateral fixed dilated pupils)

GCS Motor Score	GCS Eye Score			
	1	2	3	4
1	1	1	1	2
2	1	1	1	1
3	1	1	1	2
4	2	1	2	2
5	3	2	3	3
6	4	4	4	5

JOURNAL OF TRAUMA AND ACUTE CARE SURGERY

Figure 2: GCS score in intubated patients after Rutledge et al.

4.1.1 Rationale for the inclusion of vulnerable patients

Concerning vulnerable patients, which we might have to include in this study due to the nature of SSICH being a medical emergency, the following applies:

These participants can be included in this study according to the above-mentioned inclusion and exclusion criteria. Since this study is based on an emergency setting, time is of vital importance. For participants not able to consent, an independent physician (not involved with the study) will be consulted to confirm that the interest of the patient is preserved by participating in this study. As soon as the participants are able to consent again, they will be retrospectively informed according to the process described in 4.2 and can decide upon further participation in this study. Likewise, in the case that an independent physician was asked to confirm that the interest of the patient was preserved and the patient remains unable to consent, a legal guardian or a relative will be informed and can decide upon further participation. Information process will be the same for the legal guardian or relatives as described in 4.2 “Recruitment, screening and informed consent procedure”.

If unresponsive participants or participants incapable of judgement show any sign that they are unwilling to participate in this study, they will be excluded from this study.

4.2 Recruitment, screening and informed consent procedure

The recruitment will take place at either the emergency department or the Stroke Centre of the respective sites. Participants will be recruited by a member of the study team in the form of consecutive ongoing enrolment in daily practice as well as recruitment through a referring family physicians or peripheral hospitals to the emergency department in daily practice.

Initial screening according to the eligibility criteria pre-specified above will be performed upon admission. Some of the inclusion measurements are used in daily practice (e.g., NIHSS, GCS score evaluation, admission-imaging scan) and must be applied before informed consent is given as this is necessary to determine an underlying disease and assess study eligibility of the respective participant. These measurements serve only for the standard clinical examination used in daily emergency room practice and for testing inclusion criteria for the present study. A specific clinical examination will be performed after informed consent by the patient, a legal guardian or an independent physician was given. The investigators, a member of the study team or the attending neurosurgeon in case none of the previously named persons is available, will explain to each participant the nature of the study, its purpose, the procedures involved, the expected duration, the potential risks and benefits and any discomfort it may entail. Each participant will be informed that the participation in the study is voluntary and that the participant may withdraw from the study at any time and that withdrawal of consent will not affect the participant’s subsequent medical assistance and treatment.

The participants will be informed that the participants medical records may be examined by authorised individuals other than their treating physician.

All participants will be provided with a participant information sheet and a consent form describing the study and providing sufficient information for the participants to make an informed decision about the participation in the study. Enough time needs to be given to the participant to decide whether to participate or not, even in the setting of an emergency. However, since rapid evacuation is a vital asset of this study, we will limit this timeframe depending on the acuteness of the individual situation. The formal consent of a participant using the approved consent form, will be obtained before the participant is submitted to any study procedure aside the already mentioned necessary routine examinations of daily practice at our institution.

The consent form will be signed and dated by the investigator, a member of the study team or the attending neurosurgeon at the same time as the participant. A copy of the signed informed consent will be given to the study participants. The consent form will be retained as part of the study records and the informed consent process will be documented in the electronic patient file. All further study procedures will be commenced after the participants consented to participate in this study.

In case the patient is unable to consent due to impaired consciousness (i.e., due to the hematoma), an independent physician (who is not participating in the trial) will be asked to confirm whether the interests of the patient are preserved in the study or not. As soon as the patient regains the ability to consent, he will be retrospectively informed about the nature of the study, its purpose, the procedures involved, the expected duration, the potential risks and benefits and any discomfort the study may entail. The patient will then retrospectively be asked to provide informed consent to further participate in the study. In case a patient remains unable to consent or becomes permanently unable to consent, a legal guardian or relative will be informed about the study and will be asked to provide retrospective consent as proxy for the patient.

There will be no compensation for the participants in this study.

4.3 Study procedures

The planned overall study duration including recruitment period and follow-up for each participant is limited to 6 months after first admission to the hospital and ending with visit 7. There will be one follow-up telephone interview for long term follow-up (visit 7), where the patients contacted to see whether complications have arisen and the reintegration into daily life has been possible (taking approximately 10 minutes). The study schedule consists of 7 study visits (V1-V7), which follow the regular in- and outpatient visit schedule in patients with SSICH (clinical routine), including the following procedures with the respective time period mentioned. Only visit 7 will be outside of the clinical routine, however, only consist of a short telephone interview. All data collection for this study will begin after informed consent was given.

All imaging studies, study visits, the neurological examinations (GCS, NIHSS, MOCA) and the clinical examination are part of the daily clinical practice routine for SSICH, while the study specific examinations will consist of mRS evaluation, assessing the quality of life, patient satisfaction (Appendix 2), a telephone interview and acquiring blood samples. Blood sample will consist of collecting an aliquot of approximately 2 x 5 ml blood serum at each indicated visit. The additional blood samples for the study will be taken, if possible, during daily routine while the patient will be in the hospital (V1 & V3). For the Follow-Up visit (V6), an additional puncture will be necessary to obtain the blood samples. The PROMs Quality of Life and patient satisfaction will be assessed additionally by providing a paper-form questionnaire to the patients and their relatives. If patients are not able to complete the questionnaire, relatives will be asked to provide data. The telephone interview will follow the same structure as lined out by the telephone interview for the mRS assessment.

Collected data will be preserved in encoded form to be used in future studies, patients will be informed about the encoded retention of data and given a separate informed consent. All blood samples will be discarded after analysis and will not be used for future studies.

We designed this trial together with affected patients, caregivers and patient organization

representatives (EUPATI-CH) in the scope of PPI as pragmatic as possible, meaning that all visits and procedures were meticulously evaluated. With this we are convinced, that patients will remain in the trial as it is only little, if any at all, expenditure more than what would be the standard of care. From patients that drop out, we will analyse the data until the point of drop-out (last visit present) in an intention-to-treat fashion. Likewise, if any deviation from intervention protocol should occur, the results will be analysed as intention-to-treat and per protocol. Outcome data collected for drop-outs will consist of all study data collected to the last visit.

4.3.1 V1: Study inclusion, baseline assessment and treatment: up to 24 hours after symptom onset

Study eligibility criteria are confirmed and written informed consent is obtained from the patient. After informed consent was given, randomisation to the intervention or the control group will be conducted by a member of the study team through the CDMS SecuTrial®.

A clinical examination is performed including vital signs (resting blood pressure and heart rate, height, and weight), NIHSS, GCS, and mRS. Blood sampling for biomarkers will be obtained. Patient baseline data is acquired.

Endoscopic hematoma evacuation must be initiated within 24 hours according to the procedure described in 3.4.1 “Intervention group” (intervention group only). Surgical Baseline data is acquired.

Patients randomised to the control group will receive standard medical care according to the current guidelines as described in 3.4.2 “control group”.

4.3.2 V2: Day 1 assessment: 24 ± 6 hours after start of treatment

Clinical examination is performed as detailed for V1 except for body weight and height. All patients (control and intervention group) will receive a CT scan to assess the evolution of the hematoma volume (recurrent haemorrhage or postoperative hematoma reduction in case of the intervention group).

4.3.3 V3: Day 3 assessment: 72 ± 12 hours after treatment

Clinical examination is performed as detailed for V1 except for body weight and height. Blood sampling for biomarkers will be obtained.

4.3.4 V4: Day 7 assessment: 7±1 days after treatment or at hospital discharge

Clinical examination is performed as detailed for V1 except for body weight and height.

4.3.5 V5: Month 3 assessment: 3 months ± 14 days after treatment

Clinical examination is performed as detailed for V1 except for body weight and height and mRS. A MOCA Test is performed. Additionally, a questionnaire regarding patient satisfaction will be filled out whenever possible through a relative or otherwise together with a member of the study team and patients and their relatives will be asked to fill out a questionnaire together with a member of the study team regarding quality of life. Additionally, patients are telephonically contacted by a study-team member (blinded to the allocation) to assess the mRS according to the form in Appendix 4.

4.3.6 V6: Month 6 assessment: 6 months ± 7 weeks after treatment

Clinical examination is performed as detailed for V1 except for body weight and height and mRS. Blood sampling for biomarkers will be obtained. A cCT will be performed for all patients (control and intervention group) to evaluate possible rebleeding, hematoma resorption and the shape of the hematoma cavity. A MOCA Test is performed. Additionally, a questionnaire regarding patient satisfaction will be filled out whenever possible through a relative or otherwise together with a member of the study team and patients and their relatives will be asked to fill out a questionnaire together with a member of the study team regarding the quality of life. Additionally, patients are telephonically contacted by a study-team member (blinded to the allocation) to assess the mRS according to the form in Appendix 4.

4.3.7 V7: Month 12 assessment: 12 months ± 12 weeks after treatment

A telephone interview is conducted assessing potential morbidities of the patients and reintegration into daily life one year after intervention. Furthermore, the mRS is assessed as detailed in Visit 5 and 6.

Study period	Treatment Period				Follow-Up		
Visit	1	2	3	4	5	6	7
Time (hour, day, week)	<24 hours of symptom onset	24 ± 6 hours after treatment onset	72 ± 12 hours after treatment onset	7 ± 1 days after treatment onset	3 months ± 14 days after treatment onset	6 months ± 7 weeks after treatment onset	12 months ± 12 weeks after treatment onset
Eligibility	X						
Study consent	X						
Asses vital signs (BP,HR,height)	X	X	X	X	X	X	
Acquire NIHSS score	X	X	X	X	X	X	
Acquire GCS score	X	X	X	X	X	X	
Acquire mRS score	X	X	X	X	X**	X**	X**
Acquire blood samples (NfL, GFAP, S100B, IL)	X		X			X	
Conduct Stability CT scan*	X						
Conduct directly postoperative CT scan†		X					
Conduct postinterventional CT scan‡		X				X	
Quality of Life					X	X	
Patient Satisfaction					X	X	

Cognition					X	X	
-----------	--	--	--	--	---	---	--

**intervention group only; only required if surgery cannot be initiated within 6 hours after the first cCT scan*
†intervention group only; the directly postoperative cCT is conducted directly after surgery to assess hematoma evacuation and differentiate potential recurrent hemorrhage
‡all patients; the postinterventional cCT scan is conducted 24 hours and 6 months after the treatment start to assess potential recurrent/enlarged hematoma and defect size
***blinded telephone assessment*

4.3.8 Additional material, storage, cocomitant care as well as methods and tests used for sample collection and analysis

The imaging analysis, the additional materials and biomarkers used for this study and the procedure to reverse oral anticoagulation are explained in the following section.

4.3.8.1 Imaging analysis

In this study we will conduct cCT scans:

- At admission (clinical routine, both groups)
- Directly postoperative (clinical routine in this procedure, intra-operative or directly after surgery, intervention group only)
- At the first day after start of treatment (clinical routine in SSICH, both groups)
- At the visit after 6 months (clinical routine, both groups)

The cCT scans serve to assess the hematoma volume and to provide information about the hematoma reduction rate or increase in hematoma volume and possible rebleeding after surgery.

The pre-operative hematoma will be assessed with the $\frac{A * B * C}{2}$ formula for screening purposes due to its fast and broad applicability in emergency room settings and will then, in a second step, be validated with the neuronavigation software later on[34]. To analyse the often irregular-shaped and small postoperative hematoma volume (cCT scan directly after surgery (intervention)/ 24 hours after treatment onset(control)), the hematoma will be segmented, and its volume calculated manually on a BrainLab® planning station (or equivalent) by a trained member of the study team. Both hematoma volumes as calculated on the BrainLab® planning station (or equivalent) from cCTs at admission and directly postoperative/after 24 hours after treatment onset will be compared to assess the evolution of the hematoma volume. This increases the comparability as the $\frac{A * B * C}{2}$ formula struggles with small irregular shaped hematoma volumes.

4.3.8.2 Questionnaires

The questionnaires used in this study are the Montreal Cognitive Assessment, the PROMIS Scale v1.2 Global Health, and a questionnaire for patient satisfaction derived in our Patient and Public involvement meetings (Appendix 2 and 3). Both, MOCA and PROMIS are well established and validated questionnaires to assess cognition and quality of life respectively and were deemed the most effective and patient friendly by our PPI representatives[39, 40]. Further, the timepoint of assessment was discussed and decided upon with the PPI representatives. The questionnaire regarding patient satisfaction was created together with the PPI representatives by first collecting the most important aspects of patient satisfaction, which were then in a next step condensed to the 5 most important questions. This questionnaire is not validated in clinical trials, but a reflection of important PROMs and a product of intense collaboration with PPIs.

4.3.8.3 Biomarker analysis

Blood sampling will consist of collecting an aliquot of approximately 2 x 5 ml blood serum at the

visits as indicated above. The additional blood samples for the study will be taken, if possible, during daily routine while the patient will be in the hospital (V1 & 3). For the Follow-Up visit (V6), an additional puncture will be necessary to obtain the blood samples. The blood samples will be labelled with the patient study ID and sent to the respective site laboratories for processing. Afterwards they will be sent to the laboratories of Prof. Dr. Jens Kuhle and Prof. Dr. Raphael Guzman at the Department of Biomedicine, University Hospital Basel for biomarker analysis. The biomarkers assessed in this study are mentioned in 3.1 "Hypothesis and primary objective". The biomarkers analyzed are validated and can be used to monitor brain injury in SSICH[41-43]. NfL are highly specific structural proteins of neurons released by the disruption of axonal membranes and associated with the severity, activity, and treatment response in neuronal injury[44-46]. S100B is a non-specific marker for neuronal injury and the disruption of the blood-brain barrier which correlates with the infarction volume and clinical outcome in ischemic stroke and SSICH[47, 48]. GFAP is an intermediate filament protein expressed by astrocytes. GFAP levels are specifically higher among patients with SSICH than among patients with ischemic stroke when measured early after symptom onset[49].

We will use a novel assay to measure NfL which was developed in our Laboratory of Clinical Neuroimmunology (Prof. Dr. med. Jens Kuhle). The test is based on single-molecule array (SIMOA) technology for digital immunoassays, using the capture monoclonal antibody (mAB) 47:3, and the biotinylated detector mAB 2:1 from UmanDiagnostics (Umeå, Sweden), transferred onto the SIMOA platform. SIMOA has been shown to be more sensitive than conventional ELISA or ECL based assays to quantify NfL in serum[50].

S100B and GFAP will be measured in the laboratory of Prof. Dr. med. Guzman (S100B) and Prof. Dr. med. Kuhlen (GFAP) using a standardized immunoassay from frozen plasma samples via electrochemiluminescence (Roche Cobas Elecsys, Roche, Switzerland).

Interleukins (IL-1 α and β , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, TNF-alpha) will be measured in the laboratory of Prof. Dr. med. Guzman with electrochemiluminescent (ECL) immunosorbent assays (Meso Scale Discovery, Maryland 20877, U.S.A.). This platform allows for testing of multiple biomarkers in limited sample volumes.

The blood samples and aliquots are stored in an appropriate cooling system in a restricted area only accessible to the authorised personnel and handled under appropriate conditions.

4.3.8.4 Concomitant care

All additional treatment deemed necessary by the treating physician to address potential complications of SSICH are allowed. This includes antibiotics for any kind of infection (pulmonary, wound infection), antipsychotics in case of delirium, pain medication when needed, gastric acid inhibitors as addendum to pain medication, reversal of anticoagulation according to the guidelines but also re-surgery or secondary surgery (cross-over from BMT arm) if deemed necessary. All occurrences of such treatment will be documented within the case report form (CRF)/electronic CRF (eCRF).

4.3.8.5 Medical reversal of oral anticoagulation

Oral anticoagulation will be pharmacologically reverted according to the guidelines at the respective site and the current guidelines for ICH treatment. These foresee:

- Heparin and low molecular weight heparin will be reverted with protamin.
- Vitamin K antagonists will be reverted with 4-factor prothrombin complex concentrate and/or vitamin K.
- Rivaroxaban, Apixaban, Edoxaban and Fondoparinoux (DOACS) will be reverted with 4-factor prothrombin complex concentrate.
- Dabigatran (DOAC) will be reverted with Idarucizumab.

Based on the respective sites standard operation procedures, after surgery anticoagulation will be restarted if no new bleeding is demonstrated in the postoperative CT scan at the 3rd postoperative day. DOACS and VKA will be resumed on the 3rd or 4th postoperative day

(depending on the patients GFR, if the GFR is >30 we restart on the 2nd day after surgery or if the GFR is <30 we restart on the 3rd day after surgery) if the patient is clinically stable and no new bleeding is seen on the postoperative CT scan.

Antiplatelet drugs (Aspirin/Clopidogrel/Prasugrel or Ticagrelor) will be handled as follows:

- Aspirin will be discontinued if used as primary prophylaxis and reinstated at the 3rd postoperative day. If Aspirin is used as secondary prophylaxis, no discontinuation is required.
- Clopidogrel will be discontinued before surgery and pharmacologically reverted if necessary with platelet concentrate or Desmopressin and then reinstated at the 3rd postoperative day.
- Prasugrel will be discontinued before surgery and pharmacologically reverted if necessary with platelet concentrate and then reinstated at the 3rd postoperative day.
- Ticagrelor will be discontinued before surgery and then reinstated at the 3rd postoperative day.

4.3.9 Expected biases to the study and measures taken to reduce them

Expected biases are mentioned under 3.3.2 “Methods of minimising bias”. All involved personnel will be trained for the procedures and conduct of the protocol, its interventions and visits.

4.4 Withdrawal and discontinuation

Participants, their respective legal guardian or next of kin in case the patient remains unable to consent, can withdraw informed consent for this study whenever they want. They are withdrawn from this study if they do not meet the inclusion criteria mentioned under 4.1 “Inclusion criteria”. If patients of childbearing age get pregnant during the course of this study, they will be converted to MRI imaging instead of CT imaging but will not be ruled out.

The data of participants withdrawing prematurely (e.g. withdrawal of informed consent) is vital for the validity of the results of this trial. Currently, no sufficiently powered studies have been published on the potential benefits of ES in SSICH and it will be crucial to analyse every last patient so that the conclusion drawn from this trial is based on best possible evidence from our sample. With that, we can guarantee that future patients receive treatment based on the best possible data. The data and biological material of patients withdrawing prematurely will remain coded and used for the final outcome analysis according to the intention-to-treat principle. Participants lost that way will be marked as lost to follow-up.

5 STATISTICS AND METHODOLOGY

5.1. Statistical analysis plan and sample size calculation

The involved and responsible statistician is:

Dr. Gilles Dutilh
Senior Statistician
Department Klinische Forschung
University Hospital Basel
Spitalstrasse 12
CH-4031 Basel

5.1.1 Hypothesis

The **Null hypothesis (H₀)** describes no difference in functional outcome rates of early minimally invasive image-guided endoscopic evacuation additionally to BMT for SSICH compared to BMT alone.

The **Alternative Hypothesis (H_1)** describes a difference (either improved or worsened [two-sided testing]) functional outcome rates of early minimally invasive image guided endoscopic evacuation additionally to BMT for SSICH compared to BMT alone.

5.1.2 Sample size estimation

5.1.2.1 Derivation of assumptions for analysis of power

The power analysis is based upon the results from our own systematic review with meta-analysis, which assessed the effects of endoscopic surgery on functional outcome and mortality rates compared to BMT and CC in existing RCTs. A total of 591 patients with 312 in the control group (216 CC and 96 BMT) and 279 in the treatment group (ES) were analysed.

Favourable outcome, defined as mRS 0-3, Barthel Index ≥ 70 , Glasgow outcome scale 4-5 or an Activity of Daily Living score 1-3, 6 months after treatment was assessed as primary outcome. Favourable outcome of ES compared to BMT could be assessed in 2 studies yielding 23/64 for ES and 18/92 for BMT. This results in a cumulative Relative Risk (RR) of having a favourable outcome of 1.93 [1.12;3.33] ($p=0.02$) in favour for ES compared to BMT with insignificant heterogeneity (0%, $p=0.92$). However, we also looked at the sparse literature regarding ES in SSICH treatment.

Yao et al. conducted the first review with meta-analysis on RCTs and cohort studies clarifying the therapeutic effects of ES in SSICH compared to a combined control of CC and BMT[24]. The primary outcome was all cause mortality while secondary outcomes were poor functional outcome (mRS 4-6, Glasgow Outcome Scale 1-3 or corresponding clinical presentation) among others.

Poor functional outcome was observed in 197/348 cases in ES and 271/373 in the control resulting in a RR of having poor outcome of 0.78 [0.70;0.87] ($p<0.001$) with an insignificant heterogeneity (0%, $p=0.60$) in favour of ES. The reciprocal value of this would correspond to a RR of having a favourable outcome of 1.28 in favour of ES.

We also included a work by Sondag et al., who compared all surgical treatment (craniotomy, craniopuncture, stereotactic aspiration, MISTIE and ES) to BMT in RCTs regarding favourable functional outcome and death[19]. Favourable functional outcome was defined as good outcome, described as mRS 0-3, Glasgow Outcome Scale 4 and 5, BI ≥ 60 and an extended Glasgow Outcome scale of 5-8 points or, if none of these scores were reported, according to the definition of favourable outcome defined by the authors of the included studies. If available, the outcome assessed at 6-month follow-up was assessed, if not available the 3- or 12-month follow-up was assessed together with the 6-month outcome for the meta-analysis. A subgroup analysis comparing MIS (stereotactic aspiration, MISTIE and ES) versus BMT alone showed an RR of 1.47 to achieve favourable outcome in favour of MIS (MIS events: 575/1056, BMT events: 378/989).

When combined, the RRs of our, Yao et al.'s and Sondag et al.'s work results in a RR of 1.56 or roughly **RR of 1.6**. Additionally, we analysed the favourable outcome rates (mRS 0-3 after 3 months) of BMT from 2020-2022 from the Swiss stroke registry and found, that the rate of favourable outcome of the last two years was approximately 65%. However, all patients, even those with minimal bleeding and minimal impairment alongside patients with bleedings of >100 mL and very poor outcome, are included in the Swiss stroke registry, potentially diluting the functional outcome in favour of good outcomes rather than worse outcomes. In consideration of that aspect, a plausible assumption for the proportion of positive outcomes in the control arm is 50% (0.5).

5.1.2.2 Bayesian Sequential analysis

Based on the to-date available literature[19, 23, 24], our own meta-analysis and the data of 2020-2022 derived from the Swiss stroke registry we assume a favorable outcome around 50% for patients treated with BMT, while we anticipate a positive risk ratio of 1.6 (equaling an odds ratio of 4) towards favorable outcome for ES compared to BMT. Based on these assumptions, we explored sample sizes needed for achieving "compelling evidence", as described by

Schönbrodt & Wagenmakers[51]. Compelling evidence is defined as finding a Bayes Factor (BF) that points with a certain strength at favoring the null hypothesis or the alternative hypothesis i.e. hypothetical experiments, expressing how much more likely the data were generated from a model where both study arms have the same probability of a positive outcome, compared to a model where there is a difference in the probability of a positive outcome. Simply put, it essentially measures the evidence between the two hypothesis (For an introduction into the interpretation of Bayes Factors as indices of evidence, please refer to Jarosz & Wiley[52]). In this study, we aim to achieve a BF of 10 in favor of either hypothesis, often interpreted to represent strong evidence.

Of all the strengths when using BF as opposed to p-values for inference, two stand out:

- A BF may quantify evidence against or in favor of the null-hypothesis.
- BFs may be monitored continuously as the data is generated and collected without the need of correction schemes as needed in a classical null-hypothesis significance testing procedure.

Both strengths described above are exploited in the sample size analysis performed here: we peak at the data at any moment to see whether we have enough evidence, to allow to decide in favor of either the alternative, or the null hypothesis. Note that it does not make sense to additionally calculate a p-value at the finally achieved n. Such a p-value will, by nature, be biased towards “significance”. However, as a sensitivity analysis, we plan to perform one classic/frequentist null-hypothesis significance test at the same time as the first Bayesian analysis of the data, after 40 patients have been included in both study arms. This pre-planned hypothesis test is not biased.

5.1.2.3 Bayesian logistic regression and moment priors

We performed a Bayesian logistic regression, following the method described by Bartos & Wagenmakers to calculate an approximate Bayes factor[53]. In particular, the regression was performed using a so-called moment prior on the beta-weight of the study arms[54]. The moment prior was chosen such that it reflects our prior expectation that the true odds ratio of achieving a positive result under treatment vs under control is 4.

5.1.2.4 Stopping rule

The BF is regularly calculated until either a pre-set threshold of evidence, is achieved in favour of either of the hypotheses, or when the maximum sample size is reached. For the current study, we chose to set the maximum total sample size at 200, and the evidence threshold at a Bayes Factor of 10. In the simulations below, however, we show the expected evidence up to 160 patients per arm.

5.1.2.5 Sample size analysis results

Figure 3 shows the results of the Bayesian logistic analysis. The figure shows results for various assumptions including 1) the true proportion of positive outcomes under BMT (the different panels) and 2) the true odds ratios in favor of ES (different colored lines). The lines indicate how the probability that trial has finished (due reaching the threshold of compelling evidence of $BF = 10$) increases as the number of included patients increases (x-axis). More specifically, solid lines indicate the proportion of trials that are finished because the BF strongly favors the alternative hypothesis, the dashed lines indicate the proportion of trials where the analysis concludes in strong favor of the null hypothesis.

Comparing different panels, we see that evidence is collected quicker when the total proportion of favorable outcome for BMT is closer to 50%. Comparing different colored lines, we see that evidence is increasing quicker when the true odds ratio is larger. When inspecting the dashed




Figure 3: Results of the simulation for SSE at different probabilities and Odds Ratios. A) For a probability of favorable outcome in BMT of 30%; B) for a probability of 50% and C) for a probability of 70%

5.1.2.6 Conclusion of sample size estimation

Based on these results we assume that we will likely be able to stop collecting data before reaching **80 patients per arm (total of 160 patients) to reach a BF of 10**. We aim to collect a minimum of 40 patients per study arm. From that point on, we will perform the abovementioned BF test after every 40 new patients (about 20 per arm, exact number subject to randomization). The evidence is regularly calculated until either a pre-set level of evidence threshold is achieved in favor of either of the hypotheses (BF of 10 or 1/10 respectively, considered as strong evidence), or when the maximum sample size is reached. For the current study, we chose to set the maximum total sample size at 200 (as deemed sufficient based on a frequentist sample size estimation for the same assumptions). If this threshold is not reached, a new cost-benefit analysis of continuing to collect data will be performed. However, as described above, this is highly unlikely. After data collection is deemed completed and follow-ups at 6 months are

complete, all secondary and sensitivity analyses will be performed. For the data collected up to 40 per arm, a p-value may be calculated (sensitivity analysis) and used for a classical hypothesis test.

5.1.3 Planned statistical methods

The primary analyses are performed following the intention-to-treat principle. Additionally, per-protocol analysis will be performed for sensitivity analysis. We study the ratio of positive outcomes in both study arms by performing a Bayesian logistic regression after every 40 additional patients, using the method described by Bartos and Wagenmaker et al. using a moment prior for the regression weight [53, 54]. Data collection (and the periodical analysis of these data) will continue until a Bayes Factor of 10 (or 1/10) is achieved. The odds ratio and its 95% credible interval will be reported as based on an uninformed prior. Covariates ICH volume, presence of intraventricular bleeding, do-not-resuscitate orders, location of hematoma and centre will be included in a Bayesian logistic regression model.

Secondary analysis is performed on the secondary outcomes. For continuous variables, a Bayesian regression with normal error term is used, for time-to-event outcomes Bayesian cox-regression is used, and for binary variables Bayesian logistic regression is used. Statistical analysis is performed with R version 4.2.1 or higher (R core Team, 2022)[55]. A complete mRS shift analysis will be calculated.

At the timepoint of the first Bayesian analysis (after 40 patients have been collected in each study arm) we perform a frequentist logistic regression analysis in parallel, calculating a p-value for the null-hypothesis. In the ES arm, a number of explorative analyses are performed, studying the relation between hematoma location, hematoma size, and treatment outcome. In particular, for parameters measured over time, figures are created illustrating the development over time at both the patient level and group level.

5.1.4 Interim analysis

As described under “5.1.2.6. Conclusion of sample size estimation”, the data may be inspected any time, but we plan to perform the primary analyses after every 40 patients (20 per arm), and will stop data collection if the BF, in favor of either the null, or the alternative hypothesis is over 10.

5.1.5 Stratification for outcome analysis

Explorative stratified subgroup analysis for potential confounders (ICH volume, presence of intraventricular bleeding, do-not-resuscitate orders, location of hematoma and centre) will be conducted using Bayesian logistic regression models. An analyses of gender differences is planned.

5.1.6 Deviations from statistical analysis plan

If substantial deviations of the analysis as outlined in these sections are needed for whatever reason, the protocol will be amended. All deviations of the analysis from the protocol or from the detailed analysis plan will be listed and justified in a separate section of the final statistical report.

5.2. Handling of missing data and drop-outs

If missing data occurs, we will try to obtain the respective data needed from either the participant, their next of kin or their treating physician. If acquiring the respective missing data is not possible, we will mark the data as missing. In case of missing laboratory values, we will aim to achieve them, if this proves to be impossible, the data will be marked as missing. In case more than 5% of patients show missing data for the primary outcome across arms, multiple imputation using the

whole data set is performed.

6 REGULATORY ASPECTS AND SAFETY

6.1 Local regulations / Declaration of Helsinki

This study is conducted in compliance with the protocol, the current version of the Declaration of Helsinki, the ICH-GCP, the HRA as well as other locally relevant legal and regulatory requirements.

6.2 (Serious) Adverse Events and notification of safety and protective measures

A Serious Adverse Event (SAE) (ClinO, Art. 63) is any untoward medical occurrence that

- Results in death or is life-threatening,
- Requires in-patient hospitalisation or prolongation of existing hospitalisation,
- Results in persistent or significant disability or incapacity, or
- Causes a congenital anomaly or birth defect

Both Investigator and Sponsor-Investigator make a causality assessment of the event to the trial intervention, (see table below based on the terms given in ICH E2A guidelines). Any event assessed as possibly, probably or definitely related is classified as related to the trial intervention.

Relationship	Description
Definitely	Temporal relationship Improvement after dechallenge* Recurrence after rechallenge (or other proof of drug cause)
Probably	Temporal relationship Improvement after dechallenge No other cause evident
Possibly	Temporal relationship Other cause possible
Unlikely	Any assessable reaction that does not fulfil the above conditions
Not related	Causal relationship can be ruled out
*Improvement after dechallenge only taken into consideration, if applicable to reaction	

Both Investigator and Sponsor-Investigator make a severity assessment of the event as mild, moderate or severe. Mild means the complication is tolerable, moderate means it interferes with daily activities and severe means it renders daily activities impossible.

Reporting of SAEs (see ClinO, Art. 63)

All SAEs are documented and reported immediately (within a maximum of 24 hours) to the Sponsor-Investigator of the study.

If the SAE occurs at one of the study sites, the coordinating Investigator reports the events to the Ethics Committee concerned, within 15 days.

Exemptions from expedited reporting may be possible if the SAE is either a clear result of the underlying disease or well-known. These are defined below:

- Death
- Haemorrhagic transformation to an ischemic stroke
- Recurrent ICH
- Epileptic seizure
- Any serious, life-threatening infection (i.e., surgical site infection, pneumonia etc.)
- Persistent focal neurological impairment

Follow up of (Serious) Adverse Events

These patients will be followed according to the normal procedures of follow up in case of (S)AE within our clinic. These patients are followed periodically in an ambulatory setting until the (S)AE stabilizes or resolves.

Notification of safety and protective measures (see ClinO, Art 62, b)

If immediate safety and protective measures have to be taken during the conduct of the study, the investigator notifies the Ethics committee of these measures, and of the circumstances necessitating them, within 7 days.

6.3 (Periodic) safety reporting

An annual safety report (ASR/DSUR) is submitted once a year to the local Ethics Committee by the Investigator (ClinO, Art. 43 Abs).

6.4 Radiation

There will be no additional radiation for this study other than the planned cCT-scans, which are in accordance with routine clinical practice for SSICH. Every one of these cCT-scans will have an approximate radiation dose of 4.5 mSv. If the permitted dose guidance value (5 mSv per year if no direct benefit is expected for the participants) is exceeded at any time, the local Investigator notifies the Ethics Committee via BASEC within 7 working days of it becoming known (see ClinO, Art. 44).

6.5 Pregnancy

We plan to assess pregnancy or a possible pregnancy in women of childbearing age before inclusion. If the patient's history is positive for a pregnancy or a possible pregnancy, the patient will be excluded. If a participant gets pregnant during the study, they will receive an MRI instead of a CT scan and can continue with the study procedures. In case of pregnancy during the course of the study, the Sponsor-Investigator will be notified within a maximum of 24 hours and the outcome of the pregnancy will be followed up. The patient will be informed, that she has to contact the study team in case of pregnancy and after birth.

6.6 Amendments

Substantial changes to the study setup and study organization, the protocol and relevant study documents are submitted to the Ethics Committee for approval before implementation. Under emergency circumstances, deviations from the protocol to protect the rights, safety and well-being of human subjects may proceed without prior approval of the Ethics Committee. Such deviations shall be documented and reported to the Ethics Committee as soon as possible.

Substantial amendments are changes that affect the safety, health, rights and obligations of participants, changes in the protocol that affect study objective(s) or central research topic, changes of study site(s) or of study leader and sponsor (ClinO, Art. 29).

A list of all non-substantial amendments will be submitted once a year to the competent EC together with the ASR.

6.7 (Premature) termination of study

The Sponsor-Investigator may terminate the study prematurely according to the following circumstances:

- Arising ethical concerns
- Insufficient participant recruitment
- When the safety of the participants is doubtful or at risk (e.g., when the benefit-risk assessment is no longer positive)
- If alterations in accepted clinical practice that make the continuation of the study unwise arise
- Presence of early evidence of harm or benefit of the experimental intervention

Upon regular study termination, the Ethics Committee is notified via BASEC within 90 days (ClinO, Art. 38).

Upon premature study termination or study interruption, the Ethics Committee is notified via BASEC within 15 days (ClinO, Art. 38).

Biological materials collected until premature termination of the study will be evaluated according to the study protocol as will all acquired data to this point. The study will be published with the data collected until the point of premature termination while mentioning in the publication that a premature termination according to whatever reasons applied was chosen.

6.8 Insurance

Insurance for this study will be supplied by Helvetia Schweizerische Versicherungs AG. A contract was issued between the Helvetia Schweizerische Versicherungs AG and the Sponsor Prof. Dr. med. Raphael Guzman.

7 FURTHER ASPECTS

7.1 Overall ethical considerations

SSICH is a devastating cerebrovascular disease with currently insufficiently available effective treatment options. Our proposed approach of endoscopic evacuation of SSICH is based on pathophysiological and clinical evidence on the importance of early reduction in hematoma volume, as well as lessons learned from previous surgical trials. It is vital to evaluate new surgical methods to ameliorate patient's survival rate and to lower the social burden for the respective families. Conventional craniotomy has failed to show a significant impact on the functional outcome and mortality rates, minimally invasive surgical techniques however showed promising results. Especially ES has proven to inflict less damage to the surrounding brain tissue compared to the open surgical approaches due to its minimally invasive nature. Therefore, we plan to assess this surgical method in comparison to the current gold standard of treatment for SSICH (BMT) in a randomised controlled fashion to generate valid data on the best treatment modality for SSICH. Both are accepted treatment options for SSICH.

If ES fails to show significant effects on the specified outcome measures in the planned "interim analysis", the study will be prematurely terminated and BMT for ICH will be applied immediately for all patients.

All patients have the right to voluntarily participate in this study. Every participant, his legal guardian or his relatives have the right of information about the study and their study data.

Vulnerable populations may be included in this study as described in 4.2 "Recruitment, Screening and informed consent procedure". They might not be addressable at the time of inclusion, however, as soon as they are addressable again, they will be informed about the study according to the process in 4.2.

Overall, we consider this study to be fairly balanced between risk for the patients due to their initial condition compared to possible SAEs occurring through the surgical method proposed in this study.

7.2 Risk-benefit assessment

This study aims to prove the superiority of ES and BMT compared to BMT alone for a devastating disease with currently insufficient effective treatment. However, potential risk and SAEs can be anticipated.

This study carries relevant risk of death and disability for the included patients due to the underlying disease of SSICH, however if left untreated, outcome may be even worse with a 30-day mortality up to 45% reaching to 54% at one year. The mortality rates however can be attributed almost exclusively to the underlying disease rather than the procedure. Since this is a surgical procedure, risks like bleeding, wound infections, surgical site infection, and complications related to anaesthesiologic procedures may occur. Furthermore, the procedure might, in extremely rare cases, lead to the death of the participant. Also, due to the location of SSICH, important brain structures have to be passed to access the hematoma cavity and, despite all efforts to conserve them, might be damaged.

When compared to the potential damage inflicted by untreated SSICH however, these complications are acceptable. If our hypothesis is correct, then the participants might benefit in form of better survival and functional outcome rates from the proposed intervention.

To minimise the risk of complications, two of the senior neurosurgeons at our institution, one of them being the chief of cerebrovascular neurosurgery, have prepared a standardised surgical procedure which will be taught to all involved surgeons via proctor workshop training. The surgical procedure itself will be carried out adhering to the highest neurosurgical standards. Careful preoperative planning with BrainLab® neuronavigation (or an equivalent neuronavigation system), the minimally invasive nature of the proposed surgical method, the shorter duration of surgery, a more complete hematoma evacuation under full sight and irrigation of active bleeding sites will contribute to reducing the risk of possible AEs for the participants.

Furthermore, participants will receive the medical standard of care before and after the surgical intervention as well as in the control group and are closely monitored during their stay at the respective site.

If our hypothesis proves to be true, then surgical evacuation for SSICH may ameliorating mortality and functional outcome for future patients suffering from this devastating disease.

Overall, we acknowledge the possible risk accompanying the proposed surgical method, but it is our opinion that compared with the medical standard of care for SSICH alone or no treatment at all, these risks are acceptable and fairly balanced with the prospect of potential better survival and less morbidity as well as better functional outcome through the proposed surgical method.

7.3 Patient and Public involvement

Some of the aspects of this study were designed and developed in collaboration with representatives of the public. Aspects covered in the Patient and Public involvement were identification of patient relevant endpoints and choosing the most appropriate patient friendly tools to assess these, critically assessing, and optimising the patient visit schedule, helping to improve the comprehensibility patient ICFs and the lay summary for a broad audience. Further involvement is planned in the assessment of risk-benefit for patients during monitoring visits, consultancy regarding dissemination of the results and input to evaluate and improve further PPI involvement. For further details, please consult Appendix 2 “PPI Plan”.

8 QUALITY CONTROL AND DATA PROTECTION

8.1 Quality measures

Every assessor will be trained on how to complete the CRFs and the conduct of the questionnaires. An audit trail will maintain a record of initial entries and any changes made; time and date of entry; and username of person authorizing entry or change in the CDMS. The eCRF will be implemented by the Data management group at the DKF of the University Hospital Basel using the CDMS SecuTrial®. Data managers at the DKF Basel will implement validation rules in the CDMS. When data gets saved in an eCRF, it will be validated for completeness and discrepancies (i.e., using mandatory fields and active missing value handle). Data will be reviewed by the responsible investigator as well as an independent monitor. The monitor will raise queries using the query management system in SecuTrial®. Designated investigators have to respond to the query and confirm or correct the corresponding data. Thereafter the monitor can close the query. Range checks for scores will be implemented.

The blood samples and aliquots collected by trained personnel and are stored in an appropriate cooling system in a restricted area only accessible to the authorized personnel and handled there under appropriate conditions at the respective sites. The statistical analysis will be performed completely independent by the involved statistician at the DKF Basel. The final data set will be available in an encoded and anonymized form in accordance with the data transparency guidelines of the SNSF. For quality assurance the sponsor, the Ethics Committee or an independent trial monitor may visit the research sites. Direct access to the source data and all study related files is granted on such occasions. All involved parties keep the participant data strictly confidential.

8.2 Data recording and source data

8.2.1 Data recording

All data like scores (NIHSS, GCS, mRS, MOCA, PROMIS®, patient satisfaction), patient history and surgical baseline data will be collected or observed in daily clinical routine and transcribed to a paper CRF referring to the patient's study ID. The study ID is generated when the patient is randomized in the CDMS SecuTrial® by consecutive automatic numbering (i.e. XXX-NNN with XXX referring to the site and NNN referring to a tree digit number). Information on radiological imaging or laboratory values will be extracted from the respective system at the respective site. Data from radiological images will be directly transcribed to the paper CRF. Vital parameters (BP, HR, Temperature, Weight, Height) will be directly transferred from the electronic patient file located in the hospital information system of the respective site to the paper CRF. Laboratory values (encoded) will be provided per mail to the investigators at the Basel site by our laboratories (Clinical Neuroimmunology and Brain Ischemia) and transcribed to the paper and eCRF.

Study data will be transferred from the paper CRF to an eCRF captured via an online Clinical Data Management System (CDMS) SecuTrial®, based at the IT-department of the University Hospital Basel centrally by the main site (Basel). Additional storage capacity can be added as needed. For each enrolled study participant, an eCRF is maintained.

8.2.2 Source data

Source data for this study will be all data collected and transcribed within the paper CRF, namely scores of the mRS, NIHSS, GCS, PROMIS®, MOCA, patient satisfaction, patient and surgical baseline data and findings of the clinical examination except for the vital signs and radiological assessments as they are documented in daily practice in the electronic patient file or radiology program at the respective site and can be found there for monitoring purposes.

Morbidity will be noted in the CRF. Source data will be available and may be found in paper or electronic form.

8.3 Confidentiality and coding

A unique patient identifier (i.e., patients study ID) will be used to identify patients and a password protected list will be maintained for traceability. The patient ID is generated when the patient is enrolled in the CDMS SecuTrial® by consecutive automatic numbering (i.e., XXX-NNN with XXX referring to the site and NNN referring to a tree digit number). Only the PI or delegated study personnel at the respective site will have access to the encoding key. Enrolment and screening logs will be filed to ensure traceability at each site. The Principal Investigator and, if applicable, delegates at the sites will be authorized to do eCRF entries. The CDMS is accessible via a standard browser on devices with internet connection. Password protection and user-right management ensures that only authorized study investigators, monitors, data managers and local authorities (if necessary) will have access to the data during and after the study. User administration and user training is performed by the DKF Basel according to predefined processes. An audit trail will maintain a record of initial entries and any changes made; time and date of entry; and username of person authorizing entry or change. For each patient enrolled an eCRF must be completed. The principal investigator will be responsible for assuring that the data entered the eCRF is complete, accurate, and that the entry and updates are performed in timely manner. If a patient withdraws from the study, the reason must be noted on a dropout form of the p and eCRF. Participant's identification logs will be stored as a password protected word files and saved on protected servers of the respective study site. On CRFs and other study specific documents, participants are only identified by the patient's study ID derived by SecuTrial®. Completed paper CRFs will be kept locked in a drawer at the respective study site with access only to a very limited number of study team members. ECRFs will be secured in SecuTrial®, only accessible by the Sponsor, the PI and the study teams at the respective sites. Paper CRFs will be copied and sent to the main center (Basel) for centralized data entry into the eCRF. The Investigators and the Sponsor endorse responsibility, that nobody else will have access to the confidential data and they guarantee protection against dissemination. Trial and participant data will be handled with utmost discretion and is only accessible to authorized personnel who require the data to fulfil their duties within the scope of the study.

Biological material in this study (i.e., blood samples) are not identified by participant name but by the patient's study ID. Biological material is stored in an appropriate cooling system in a restricted area only accessible to the authorized personnel and handled under appropriate conditions at the respective sites. The material will be sent coded by the patient's study ID to 1) the laboratory of Prof. Dr. med. J. Kuhle (NfL, GFAP) or 2) to the laboratory of Prof. Dr. med. R. Guzman (S100B, Interleukins). The results will be provided by mail to the study investigators in Basel and will not show in the respective hospitals electronic record system. The material's location is tracked by a laboratory log which is kept in the sites investigator site file (ISF). Biological material will be discarded after analysis as according to respective hospitals regulations for biological waste. All study data, except blood samples, will be archived for a minimum of 10 years after study termination or premature termination of the clinical trial.

8.4 Retention and destruction of study data and biological material

The study protocol and the informed consents for further usage of the collected data will be archived for 10 years after study termination or premature termination of the study to be able to prove that informed consent for further usage was given. Biological material will be kept for a duration of 1 week after obtaining the final analysis. Disposal of the biological material will be in accordance with the hospital regulations concerning body fluids and blood samples from patients. The collected study data might be used in encoded form for future trials. If no consent for further usage of the data is given, the collected study data will be destroyed after 10 years and not be used for further studies.

8.4.1 Dissemination of study results

The documentation accompanying the data will consist out of the Data Record Table (DRT) exported from the CDMS SecuTrial®, therefore containing all data collected on paper CRF. It is an Excel file summarizing the questions and variables collected in the eCRF. The Excel file consists out of the following sheets:

- **Configuration:** An overview sheet of the internal project's name, eCRF version and which extended features of SecuTrial® have been activated.
- **Form overview:** In this sheet, all available forms of the eCRF will be listed and the full visit plan (name, day of visit, type of visit, possible deviations in days) will be shown. For each form the visits in which it is available (or whether it is visit independent) and the name of the .csv table when exported will be given.

There will be one sheet for each form, containing the names of the form and a .csv table. All variables stored in a table will be listed in separate rows, with the following metadata:

- Question and description text as shown in the eCRF, caption of the variable in the eCRF, type of the variable (e.g. text field with maximal number of characters, date, number item with maximal number of digits, radio button or drop down selection with list of available answers, check box, date), name of the variable in the exported .csv tables and if applicable any additional rules (e.g. mandatory item, optional item, "hide item if" with corresponding conditional)

The metadata variables (e.g. patient-ID, visit number, date of last edit, person entering data) and potential details regarding processing and analysis saved with the eCRF data in the exported tables will be specified in an additional Excel file. The patient-ID will serve as the persistent identifier. During the conduct of the study, we plan to consult patient organization representatives to discuss possibilities to best disseminate the results of the trial. Thus, the following are only tentative plans. We plan to disseminate the results over 1) our trial website, 2) over the SNSF platform and 3) with the help of PO representatives to the respective patient organizations, 4) by publishing the results open-access in a peer-reviewed journal 5) social media (linked-in, twitter etc.).

8.4.2 Reproducibility

The Ordinance of 20 September 2013 on Clinical Trials in Human Research (Clinical Trials Ordinance, ClinO) ordains that handling of health-related personal data in connection with a clinical trial must be restricted to those persons who require this data to fulfil their duties. The Federal Act of 30 September 2011 on research involving Human Beings (Human Research Act, HRA) requires an informed consent of the person, the legal representative or next of kin for reuse of personal data. Personal data may only be disclosed to third parties provided the person has given written consent in each case. In exceptional cases, further use of data for research purposes may be made if informed consent is absent (HRA Art. 34). Researchers who wish to reuse the data will have to obtain authorization of the responsible ethics committee as ordained in the Ordinance of 20 September 2013 on Human Research with the exception of clinical Trials (Human Research Ordinance, HRO). The definition of "further use" in the HRO in particular includes the storage in databases and making accessible or available or transferring of health-related personal data already collected. A transfer of research data to a data repository would therefore violate national law. Although some repositories allow storing data none publically and restricting data access to specific users, they do not support restricted access to a subset of stored variables. Since the responsible ethics committee can exclude certain variables from reuse in a specific project application, restriction to subsets is a required feature.

The only way to circumvent the HRA would be an anonymization of the data, i.e., the masking or deleting of all items which, when combined, would enable to identify a patient without

disproportionate effort. Health-related personal data are considered correctly coded in accordance with the HRA if, from the perspective of a person who lacks access to the key, they are to be considered anonymized (HRO Art. 26). Since the investigator must retain all documents required for the identification and follow-up of participants for at least ten years after the completion of a clinical trial (ClinO Art. 45), data may appear anonymized to third parties, while in fact the HRA considers them coded and forbids reuse without the persons' consents. Additionally, an anonymization would make the combination of these data with routine data and data from other clinical trials impossible, which is the most important and most common reason for reuse of data in clinical research. Furthermore, it would counteract the efforts of the government-funded Swiss Personalized Health Network (SPHN), which has given priority to effective exchange of patient data.

Instead of transferring the data on a repository, the Department of Clinical Research (DKF) of the University of Basel will act as an independent Data Access Committee (DAC) and store the data at time of publication on secure servers, maintained and backed-up by the IT-Department of the University Hospital Basel. Researchers who wish to reuse data may submit a project synopsis to the DKF.

The DKF as independent DAC will answer formal request of applicants, review and submit the project documents to the responsible ethics committee(s) and (upon approval) securely transfer the requested data to the applicants.

Metadata describing the type, size and content of the datasets will be shared along with the study protocol and case report forms on the public repository dataverse.harvard.edu.

Additionally, the CRFs will be uploaded on medical-data-models.org and all variables will be annotated by their Unified Medical Language System Concept Unique Identifier (UMLS CUI) to improve findability for other clinicians. With the metadata registered on a public repository together with a reference to the DAC, this procedure will adhere to the FAIR principles to the best of the legal limitations for clinical research in Switzerland.

The results of this study will be published in a peer-reviewed medical journal, independent of the results and the statistical code is made available upon request. A data sharing statement referring researchers to the DKF for data access will be contained in the study protocol and publication.

9 MONITORING AND REGISTRATION

Monitoring duties will be provided by the Clinical Trial Unit of the University Hospital Basel. The study sites will be initiated with a site initiation visit and then regularly checked during the course of the study as defined in the monitoring plan. All informed consents, source data, e.g., CRF, eCRF and laboratory results, the trial master file and the investigator site file will be monitored. All source data and all documents will be made accessible to monitors and questions will be answered during monitoring through the study staff. The data and safety monitoring committee is independent from the investigator team and consists of an expert in the field, a statistician, a monitor and a data analyst. Additionally, a Patient expert with experience in regulatory affairs will be member of the DSMB, responsible for assessing risk and benefits for the patients during this trial. An independent Clinical Outcome Event Committee will re-evaluate all SAEs occurring in the study and confirm or correct the assessment of the investigators at the hand of the DSMB. The CEC will send the report of their assessment to the DSMB. An assessment will occur whenever 40 patients have been included.

This study will be registered in the Swiss National Clinical Trial Portal and in the Clinicaltrials.gov Registry Platform.

10. FUNDING / PUBLICATION / DECLARATION OF INTEREST

10.1 Funding

This study is funded by the Swiss National Science Foundation (SNSF), grant number 33IC30_213916. Additionally, applications to ProPatient and the Bangerter-Rhyner Foundation are planned. A preparatory grant from the SNSF (33IC30_213916) for the Patient and Public Involvement was received and funded the PPI during the set-up phase. The funders will have no involvement in the planned study design and will not have any role during its execution, analysis and interpretation of data or decision to submit results.

10.2 Publication

The results of this study are expected to be published in a peer reviewed journal of neurosurgery or neurology with all following persons authorized to access, listed as authors. We confirm that if gender effects are observed, they will be published in the final study report. If an analysis is performed but no gender effects are observed, this will also be published.

Authors will be:

- Prof. Dr. med. Raphael Guzman, Sponsor, *Vice-Chairman, Department of Neurosurgery, Chief of cerebrovascular neurosurgery, University Hospital Basel, Switzerland*
- Prof. Dr. med. Jehuda Soleman, Principal-Investigator Basel, *Senior Neurosurgeon, Head of Clinical Research Department of Neurosurgery, University Hospital Basel, Switzerland*
- Prof. Dr. med. Urs Fischer, Sub-Investigator, *Chair of Neurology, Head of the Department of Neurology, University Hospital Basel, Switzerland*
- Dr. med. Tim Jonas Hallenberger, Sub-Investigator, *MD PhD Student, Department of Neurosurgery, University Hospital Basel, Switzerland*
- Dr. Gilles Dutilh, Senior Statistician, *Clinical Trial Unit, University Hospital Basel, Switzerland*
- Site PIs of all included sites

Associates will be:

- Prof Dr. med. Jens Kuhlen, Analysis of NfL, *Head of Multiple Sclerosis research, Department of Neurology, University Hospital Basel, Switzerland*

Patient and Public Involvement representatives will be:

- Andrea Sarti Vogt, Individual Patient, Identification of relevant PROMs, Organisation (Protocol design, ICF forms), Lay summary, Evaluation of PPI Involvement
- Claudia Böni, Caregiver, Identification of relevant PROMs, Organisation (Protocol design, ICF forms), Lay summary, Evaluation of PPI Involvement
- Rosine Mucklow, Patient organization representative and Patient Expert, Identification of relevant PROMs, Organisation (Protocol design, ICF forms), Lay summary, Monitoring, Evaluation of PPI Involvement

The clinical trial unit of the University Hospital Basel will be involved in data management, statistical calculations, monitoring and PPI involvement. An independent data and safety monitoring board will be responsible for conducting the planned “interim analysis”.

Contribution:

RG, JS, LB, UF and TJH conceived the study protocol, and all authors drafted the protocol. RG is expected to be the grant holder. RG, JS, TJH and UF implemented the study. TJH designed the PPI aspects of this study. RG and JK will provide the laboratory material and locations for biomarker analysis. GD will perform statistical analysis. All authors critically revised the protocol

before submission to the local ethics committee.

10.3 Declaration of interest

The authors declare no conflict of interest for the present study. Mr Tim Hallenberger discloses, that he receives a MD PhD scholarship jointly by the SNSF and the Swiss Academy of Medical Sciences. Profs. Jehuda Soleman and Raphael Guzman disclose that they receive funding for the present study by the Swiss National Science Foundation as outlined under “10.1 Funding”.

11. REFERENCES

1. Common Terminology Criteria for Adverse Events (CTCAE)
https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
2. Declaration of Helsinki
<https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>
3. Federal Act on Data Protection (FADP)
<https://www.admin.ch/opc/en/classified-compilation/19920153/index.html>
4. Human Research Act (HRA)
<https://www.admin.ch/opc/de/classified-compilation/20061313/index.html>
5. International Conference on Harmonization (ICH) E6(R2) Guideline for Good Clinical Practice
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2_Step_4_2016_1109.pdf
6. International Conference on Harmonization (ICH) E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002749.pdf
7. Ordinance on Clinical Trials in Human Research (ClinO)
<https://www.admin.ch/opc/de/classified-compilation/20121176/index.html>

Background and rationale

1. Chan, A.W., et al., *SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials*. BMJ, 2013. **346**: p. e7586.
2. Calvert, M., et al., *Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension*. JAMA, 2018. **319**(5): p. 483-494.
3. Feigin, V.L., et al., *Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century*. Lancet Neurol, 2003. **2**(1): p. 43-53.
4. Krishnamurthi, R.V., et al., *Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010*. Lancet Glob Health, 2013. **1**(5): p. e259-81.
5. Dennis, M.S., *Outcome after brain haemorrhage*. Cerebrovasc Dis, 2003. **16 Suppl 1**: p. 9-13.
6. Qureshi, A.I., et al., *Changes in cost and outcome among US patients with stroke hospitalized in 1990 to 1991 and those hospitalized in 2000 to 2001*. Stroke, 2007. **38**(7): p. 2180-4.
7. Christensen, M.C., S. Mayer, and J.M. Ferran, *Quality of life after intracerebral hemorrhage: results of the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial*. Stroke, 2009. **40**(5): p. 1677-82.
8. Xi, G., R.F. Keep, and J.T. Hoff, *Mechanisms of brain injury after intracerebral haemorrhage*. Lancet Neurol, 2006. **5**(1): p. 53-63.

9. Huang, F.P., et al., *Brain edema after experimental intracerebral hemorrhage: role of hemoglobin degradation products*. J Neurosurg, 2002. **96**(2): p. 287-93.
10. Hemphill, J.C., 3rd, et al., *The ICH score: a simple, reliable grading scale for intracerebral hemorrhage*. Stroke, 2001. **32**(4): p. 891-7.
11. Cordonnier, C., et al., *Intracerebral haemorrhage: current approaches to acute management*. Lancet, 2018. **392**(10154): p. 1257-1268.
12. Greenberg, S.M., et al., *2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association*. Stroke, 2022. **53**(7): p. e282-e361.
13. Anderson, C.S., et al., *Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage*. N Engl J Med, 2013. **368**(25): p. 2355-65.
14. Qureshi, A.I., et al., *Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage*. N Engl J Med, 2016. **375**(11): p. 1033-43.
15. de Oliveira Manoel, A.L., *Surgery for spontaneous intracerebral hemorrhage*. Crit Care, 2020. **24**(1): p. 45.
16. Mendelow, A.D., et al., *Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial*. Lancet, 2005. **365**(9457): p. 387-97.
17. Mendelow, A.D., et al., *Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial*. Lancet, 2013. **382**(9890): p. 397-408.
18. Guo, G., et al., *Efficacy and safety of four interventions for spontaneous supratentorial intracerebral hemorrhage: a network meta-analysis*. J Neurointerv Surg, 2020.
19. Sondag, L., et al., *Neurosurgical Intervention for Supratentorial Intracerebral Hemorrhage*. Ann Neurol, 2020. **88**(2): p. 239-250.
20. Morgan, T., et al., *Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial*. Acta Neurochir Suppl, 2008. **105**: p. 147-51.
21. Hanley, D.F., et al., *Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial*. Lancet Neurol, 2016. **15**(12): p. 1228-1237.
22. Hanley, D.F., et al., *Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial*. Lancet, 2019. **393**(10175): p. 1021-1032.
23. Scaggiante, J., et al., *Minimally Invasive Surgery for Intracerebral Hemorrhage*. Stroke, 2018. **49**(11): p. 2612-2620.
24. Yao, Z., et al., *Effect and Feasibility of Endoscopic Surgery in Spontaneous Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis*. World Neurosurg, 2018. **113**: p. 348-356.e2.
25. Kellner, C.P., et al., *Long-term functional outcome following minimally invasive endoscopic intracerebral hemorrhage evacuation*. Journal of NeuroInterventional Surgery, 2020. **12**(5): p. 489.
26. Li, M., et al., *Different surgical interventions for patients with spontaneous supratentorial intracranial hemorrhage: A network meta-analysis*. Clin Neurol Neurosurg, 2020. **188**: p. 105617.
27. Steiner, T., et al., *European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage*. Int J Stroke, 2014. **9**(7): p. 840-55.
28. Kellner, C.P., et al., *Time to Evacuation and Functional Outcome After Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation*. Stroke, 2021. **52**(9): p. e536-e539.
29. Morgenstern, L.B., et al., *Rebleeding leads to poor outcome in ultra-early craniotomy for intracerebral hemorrhage*. Neurology, 2001. **56**(10): p. 1294-9.

30. Wang, Y.F., et al., *The optimal time-window for surgical treatment of spontaneous intracerebral hemorrhage: result of prospective randomized controlled trial of 500 cases*. 2008: p. 141-145.
31. Green, T.L., N. Newcommon, and A. Demchuk, *Quality of life and caregiver outcomes following decompressive hemicraniectomy for severe stroke: a narrative literature review*. Can J Neurosci Nurs, 2010. **32**(2): p. 24-33.
32. van Asch, C.J., et al., *Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis*. Lancet Neurol, 2010. **9**(2): p. 167-76.
33. van Swieten, J.C., et al., *Interobserver agreement for the assessment of handicap in stroke patients*. Stroke, 1988. **19**(5): p. 604-7.
34. Kothari, R.U., et al., *The ABCs of measuring intracerebral hemorrhage volumes*. Stroke, 1996. **27**(8): p. 1304-5.
35. Bruno, A., et al., *Simplified modified rankin scale questionnaire: reproducibility over the telephone and validation with quality of life*. Stroke, 2011. **42**(8): p. 2276-9.
36. Baggio, J.A., et al., *Validation of a structured interview for telephone assessment of the modified Rankin Scale in Brazilian stroke patients*. Cerebrovasc Dis, 2014. **38**(4): p. 297-301.
37. Hallenberger, T.J., R. Guzman, and J. Soleman, *Minimally invasive image-guided endoscopic evacuation of intracerebral haemorrhage: How I Do it*. Acta Neurochir (Wien), 2022.
38. Rutledge, R., et al., *Appropriate use of the Glasgow Coma Scale in intubated patients: a linear regression prediction of the Glasgow verbal score from the Glasgow eye and motor scores*. J Trauma, 1996. **41**(3): p. 514-22.
39. Nasreddine, Z.S., et al., *The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment*. J Am Geriatr Soc, 2005. **53**(4): p. 695-9.
40. Salinas, J., et al., *An International Standard Set of Patient-Centered Outcome Measures After Stroke*. Stroke, 2016. **47**(1): p. 180-6.
41. Brunswick, A.S., et al., *Serum biomarkers of spontaneous intracerebral hemorrhage induced secondary brain injury*. J Neurol Sci, 2012. **321**(1-2): p. 1-10.
42. Senn, R., et al., *Potential role of blood biomarkers in the management of nontraumatic intracerebral hemorrhage*. Cerebrovasc Dis, 2014. **38**(6): p. 395-409.
43. Alex Matos Ribeiro, J., et al., *Prognostic molecular markers for motor recovery in acute hemorrhagic stroke: A systematic review*. Clin Chim Acta, 2021. **522**: p. 45-60.
44. Byrne, L.M., et al., *Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis*. Lancet Neurol, 2017. **16**(8): p. 601-609.
45. Kuhle, J., et al., *Serum neurofilament is associated with progression of brain atrophy and disability in early MS*. Neurology, 2017. **88**(9): p. 826-831.
46. Barro, C., et al., *Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis*. Brain, 2018. **141**(8): p. 2382-2391.
47. Foerch, C., et al., *Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction*. Arch Neurol, 2005. **62**(7): p. 1130-4.
48. Delgado, P., et al., *Plasma S100B level after acute spontaneous intracerebral hemorrhage*. Stroke, 2006. **37**(11): p. 2837-9.
49. Luger, S., et al., *Glial Fibrillary Acidic Protein Serum Levels Distinguish between Intracerebral Hemorrhage and Cerebral Ischemia in the Early Phase of Stroke*. Clin Chem, 2017. **63**(1): p. 377-385.
50. Kuhle, J., et al., *Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa*. Clin Chem Lab Med, 2016. **54**(10): p. 1655-61.
51. Schönbrodt, F.D. and E.J. Wagenmakers, *Bayes factor design analysis: Planning for compelling evidence*. Psychon Bull Rev, 2018. **25**(1): p. 128-142.

52. Jarosz, A.F. and J. Wiley, *What Are the Odds? A Practical Guide to Computing and Reporting Bayes Factors*. The Journal of Problem Solving, 2014. **7**(1).
53. Bartoš, F. and E.-J. Wagenmakers, *A general approximation to nested Bayes factors with informed priors*. Stat, 2023. **12**(1): p. e600.
54. Johnson, V.E. and D. Rossell, *On the Use of Non-Local Prior Densities in Bayesian Hypothesis Tests*. Journal of the Royal Statistical Society. Series B (Statistical Methodology), 2010. **72**(2): p. 143-170.
55. RCoreTeam, *R: A language and environment for statistical computing*. . 2022, R Foundation for artistically Computing: Vienna.

Appendix 1: Schedule of assessments

Study period	Treatment Period				Follow-Up		
	1	2	3	4	5	6	7
Visit							
Time (hour, day, week)	<24 hours of symptom onset	24 ± 6 hours after treatment onset	72 ± 12 hours after treatment onset	7 ± 1 days after treatment onset	3 months ± 14 days after treatment onset	6 months ± 7 weeks after treatment onset	12 months ± 12 weeks after treatment onset
Eligibility	X						
Study consent	X						
Asses vital signs (BP,HR,height)	X	X	X	X	X	X	
Acquire NIHSS score	X	X	X	X	X	X	
Acquire GCS score	X	X	X	X	X	X	
Acquire mRS score	X	X	X	X	X**	X**	X**
Acquire blood samples (NfL, GFAP, S100B, IL)	X		X			X	
Conduct Stability CT scan*	X						
Conduct directly postoperative CT scan†		X					
Conduct postinterventional CT scan‡		X				X	
Quality of Life					X	X	
Patient Satisfaction					X	X	
Cognition					X	X	

*intervention group only; only required if surgery cannot be initiated within 6 hours after the first cCT scan

†intervention group only; the directly postoperative cCT is conducted directly after surgery to assess hematoma evacuation and differentiate potential recurrent hemorrhage

‡all patients; the postinterventional cCT scan is conducted 24 hours and 6 months after the treatment start to assess potential recurrent/enlarged hematoma and defect size
***blinded telephone assessment*

Appendix 2: Patient and Public Involvement Plan

Activity	What was the role of the PPI contributor(s)?	What was the objective?	How did it influence the study submitted? Please describe the benefit of the involvement.
<p>Include an individual patient, a caregiver and a patient organization representative to identify and prioritize patient relevant outcome measures (PROMs) as secondary outcome measures.</p>	<p>The PPI contributors participated in a group meeting and gave input and advice on identifying important PROMs from the patient’s perspective.</p>	<p>Ensuring that relevant PROMs are identified as secondary outcome measures</p>	<p>With the help of the PPIs we identified patient satisfaction, cognitive outcome of patients as well as patient’s quality of life as new and underreported secondary outcomes. We further worked together to choose the optimal questionnaires and arrived at the PROMIS® questionnaire for Quality of Life, the MOCA for cognition and devised together the most important aspects of patient satisfaction in the hospital and follow-up setting. We also determined together at which time points these outcomes should be assessed and what would be reasonable from a patients perspective.</p>
<p>Include an individual patient, a caregiver and a Patient Organization representative to identify and advice on potential weak spots in the study procedures, to optimize the study design and procedures to patient</p>	<p>In a first step, the PPI contributors were required to read and understand the study protocol in advance of the group meeting. Then, they participated in a group meeting and gave advice on identified weak spots in the study and</p>	<p>To identify possible weak spots in the study procedures and to optimize the study design and conduct into a patient friendly design to ultimately improve enrolment rates and study retention</p>	<p>Together with the PPIs, we improved and simplified our visit schedule. Specifically, we reduced the blood sampling to the most essential number of samples, thought about training tools to improve psychological patient</p>

<p>friendly design and procedures and to find the correct follow-up time</p>	<p>procedures to help optimize the study schedule for involved patients.</p>		<p>care (i.e. on ICU), developed the idea to also include patients relatives for assessing the patient satisfaction as this would yield more valid results, changed the timing of follow-up visits and confirmed 6 month as optimal endpoint of the study from a patients perspective</p>
<p>Include an individual patient and a caregiver to give advice and input for formulating an easily understandable patient informed consent form. As our PO Representative was very experienced, we didn't want to miss her opinion in this process despite being not initially planned</p>	<p>In a first step, the PPI contributors were required to read and critically assess the informed consent form regarding understandability, clearness and which expectations are addressed and which are not. In a second step, they were required to give their assessment/feedback to the investigators and advise on potential improvements to the informed consent form</p>	<p>To create a easily understandable and appealing informed consent form for potential patients and their relatives to correctly address the patient expectations</p>	<p>With the help of the PPIs we established an easy to understand patient informed consent form (ICF). We further clarified aspects of the ICF such as the benefit of the study and the concept of the two treatment methods. We further added more explanation on the surgical technique and the best medical treatment. Lastly we improved the visual design of the ICF as some aspects were confusing and not easy to grasp.</p>
<p>Consulting an individual patient or caregiver to review the lay summary of the study and its goals for the grant proposal and later publication on our website. With this we had again the help from all our PPIs as the opinions of a caregiver and a Patient Organization representative were very valuable.</p>	<p>The individual patient or caregiver was required to have read the lay summary to assess and give feedback whether it is clearly understandable or not.</p>	<p>To ensure the lay summary of the proposed project is easily understandable for the general public</p>	<p>We identified and removed wording problems, potentially making the summary less suggestive while we also determined that the summary reflected the important aspects of the study and is easily understandable.</p>

Phase	Activity	What is the role of the PPI contributor(s)?	What is the objective?
Management and study process	Consulting a patient expert to be part of the data and safety monitoring board and conducting risk-benefit assessment and patient safety aspects within the DSMB.	The patient expert is required to have experience in safety and regulation procedures. The PE is expected to actively participate in the DSMB and faithfully complete his appointed task of assessing risk and benefits for the involved participants.	Ensure patient perspective is taken into consideration for all questions and issues (i.e. safety) that arise during the study. Providing a patient relevant perspective to risks and benefits of the study and potential safety aspects.
Data analysis/Management and study process	As member of the DSMB, the Patient Expert will inadvertently be confronted with results from the regular interim analysis due to the nature of Bayesian modelling. The Patient Expert assesses the risk-benefit ratio according to these results together with the trial statistician	The patient expert is required to have experience in safety and regulation procedures and basic statistic knowledge. The PPI is expected to actively participate in the DSMB and faithfully complete his appointed task together with the trial statistician.	Ensure that important trends in the risk-benefit assessment are detected and that patient safety is maintained in collaboration with the rest of the DSMB.
Dissemination and implementation	Consulting patient an organization representative (i.e. EUPATI-CH or Fragile Suisse) and a caregiver and a patient regarding dissemination and communication of the study results to a broad audience in a patient friendly manner.	The PPI team is expected to collaborate and actively participate in preparing the study results in an appealing and easily understandable fashion together with the study team. The PPI team is required to understand the meaning of the results and its impact on the community they represent.	Ensure that the study results are clear, in lay language and appealing to effectively disseminate them in the relevant population so that the affected patients are addressed and aware of the results
Evaluation	Consulting the PPI Team involved in the study to evaluate the impact of PPIs at different study phases/milestones	The PPIs are expected to attend a debriefing and to actively participate in evaluating the impact of PPI, giving	Gaining important insights into the benefits and the impact PPI had on different phases/milestones of

	(i.e. Ethics approval etc.), assessing "lessons learned" and potential improvements for future PPI involvement.	feedback regarding PPI involvement in the project and discuss potential improvements for future PPI activities/involvement. For that the PPI is required to have participated in previous PPI activities.	the study, discussing "lessons learned" and potential improvements for future PPI involvement in the present or future studies
--	---	---	--

Appendix 3 – Patient satisfaction Questionnaire

Questionnaire Patient Satisfaction


VISIT 5

Question	Score (1=worst, 5=best)	
1. Did you have the impression that you were well looked after?	<input type="checkbox"/> 1 point	<input type="checkbox"/> not known
2. Were all of your questions answered properly (i.e. what the further problems of the disease could be, what happens in the future) and did you have the impression that you were taken serious?	<input type="checkbox"/> 2 points	<input type="checkbox"/> not known
3. Did you have the impression that enough time was allocated for you during your in-patient visit?	<input type="checkbox"/> 3 points	<input type="checkbox"/> not known
4. How satisfied are you with the treatment outcome (i.e. functional outcome, disability etc.)?	<input type="checkbox"/> 4 points	<input type="checkbox"/> not known
5. How satisfied are you with your treatment overall?	<input type="checkbox"/> 5 points	<input type="checkbox"/> not known
Total points		

VISITE 6

Question	Score (1=worst, 5=best)	
1. Did you have the impression that you were well looked after?	<input type="checkbox"/> 1 point <input type="checkbox"/> 2 points <input type="checkbox"/> 3 points <input type="checkbox"/> 4 points <input type="checkbox"/> 5 points	<input type="checkbox"/> not known
2. Were all of your questions answered properly (i.e. what the further problems of the disease could be, what happens in the future) and did you have the impression that you were taken serious?	<input type="checkbox"/> 1 point <input type="checkbox"/> 2 points <input type="checkbox"/> 3 points <input type="checkbox"/> 4 points <input type="checkbox"/> 5 points	<input type="checkbox"/> not known
3. Did you have the impression that enough time was allocated for you during your in-patient visit?	<input type="checkbox"/> 1 point <input type="checkbox"/> 2 points <input type="checkbox"/> 3 points <input type="checkbox"/> 4 points <input type="checkbox"/> 5 points	<input type="checkbox"/> not known
4. How satisfied are you regarding the information received for the future after the trial?	<input type="checkbox"/> 1 point <input type="checkbox"/> 2 points <input type="checkbox"/> 3 points <input type="checkbox"/> 4 points <input type="checkbox"/> 5 points	<input type="checkbox"/> not known
5. How satisfied are you with your treatment overall?	<input type="checkbox"/> 1 point <input type="checkbox"/> 2 points <input type="checkbox"/> 3 points <input type="checkbox"/> 4 points <input type="checkbox"/> 5 points	<input type="checkbox"/> not known
Total points		

Appendix 4 - Standardized telephone assessment for the primary outcome



As presented in „[Simplified Modified Rankin Scale Questionnaire](#)
 Askiel Bruno, MD , Abiodun E. Akinwuntan, PhD , Chen Lin, BS , Brian Close, BS , Kristin Davis, MD , Vanessa Baute, MD , Tia Aryal, MD , Desiree Brooks, BS , David C. Hess, MD , Jeffrey A. Switzer, DO , and Fenwick T. Nichols, MD”

Abschlusszertifikat

Umschlag-ID: 1D3867AB36484F76B1EF70F6C37B3C50

Status: Abgeschlossen

Betreff: EMINENT-ICH Protocol to be signed for Amendment 3.0

Quellumschlag:

Dokumentenseiten: 57

Signaturen: 15

Zertifikatsseiten: 10

Initialen: 0

Signatur mit Anleitung: Aktiviert

Umschlag-ID-Stempel: Aktiviert

Zeitzone: (UTC+01:00) Amsterdam, Berlin, Bern, Rom, Stockholm, Wien

Umschlagsteller:

Tim Hallenberger

tim.hallenberger@usb.ch

IP-Adresse: 145.250.209.1

Eintragsverfolgung

Status: Original

Inhaber: Tim Hallenberger

Standort: DocuSign

27. Juli 2024 | 16:37

tim.hallenberger@usb.ch

Unterzeichnereignisse**Signatur****Zeitstempel**

Alex Alfieri

alex.alfieri@ksw.ch

Sicherheitsstufe: E-Mail, Kontoauthentifizierung
(keine)DocuSigned by:
Alex Alfieri
36121247A44E48F...Signaturübernahme: Vorgegebener Stil
Mit IP-Adresse: 194.209.83.233

Gesendet: 27. Juli 2024 | 17:05

Eingesehen: 27. Juli 2024 | 18:30

Signiert: 27. Juli 2024 | 18:32

Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:

Akzeptiert: 09. Februar 2024 | 23:36

ID: 39ddf8e7-acec-4bf0-bb23-9a3aae19720a

Jehuda Soleman

jehuda.soleman@usb.ch

Sicherheitsstufe: E-Mail, Kontoauthentifizierung
(keine)DocuSigned by:
Jehuda Soleman
BD382A2368F04E6...Signaturübernahme: Auf Gerät gezeichnet
Mit IP-Adresse: 185.144.73.86
Mit Mobilgerät signiert

Gesendet: 27. Juli 2024 | 17:05

Eingesehen: 27. Juli 2024 | 22:24

Signiert: 27. Juli 2024 | 22:25

Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:

Nicht über DocuSign angeboten

Kevin Akeret

kevin.akeret@usz.ch

Sicherheitsstufe: E-Mail, Kontoauthentifizierung
(keine)Signed by:
Kevin Akeret
79D7BF1D687C48D...Signaturübernahme: Vorgegebener Stil
Mit IP-Adresse: 72.187.5.201
Mit Mobilgerät signiert

Gesendet: 27. Juli 2024 | 17:05

Eingesehen: 28. Juli 2024 | 00:20

Signiert: 28. Juli 2024 | 00:21

Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:

Akzeptiert: 28. Juli 2024 | 00:20

ID: 5e2d73bc-d3a0-4ecc-934c-7fbe1f5ecae8

PD Dr. Andrea Cardia

andrea.cardia@eoc.ch

Sicherheitsstufe: E-Mail, Kontoauthentifizierung
(keine)Firmato da:
PD Dr. Andrea Cardia
8CF60A641D8843D...Signaturübernahme: Vorgegebener Stil
Mit IP-Adresse: 185.225.93.10

Gesendet: 27. Juli 2024 | 17:05

Erneut gesendet: 08. August 2024 | 17:42

Erneut gesendet: 09. August 2024 | 07:26

Erneut gesendet: 12. August 2024 | 09:30

Eingesehen: 12. August 2024 | 09:31

Signiert: 12. August 2024 | 09:32

Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:

Akzeptiert: 12. August 2024 | 09:31

ID: 5ba76b7a-62de-4c59-9b07-b7ed3ac0138b

Unterzeichnereignisse

PD Dr. Christian Zweifel
christian.zweifel@ksg.ch
Sicherheitsstufe: E-Mail, Kontoauthentifizierung
(keine)

Signatur

Signiert von:

15BA7969F57345B...

Signaturübernahme: Vorgegebener Stil
Mit IP-Adresse: 195.65.23.196


Zeitstempel

Gesendet: 27. Juli 2024 | 17:05
Eingesehen: 05. August 2024 | 19:04
Signiert: 05. August 2024 | 19:05

Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:

Akzeptiert: 05. August 2024 | 19:04
ID: ecb22865-8722-4f39-8f15-a57e9ecc252e

PD Dr. Isabel Hostettler
isabel.hostettler@kssg.ch
Sicherheitsstufe: E-Mail, Kontoauthentifizierung
(keine)

Signiert von:

487E5161F4524C6...

Signaturübernahme: Vorgegebener Stil
Mit IP-Adresse: 193.134.32.99

Gesendet: 27. Juli 2024 | 17:05
Eingesehen: 27. Juli 2024 | 17:49
Signiert: 27. Juli 2024 | 17:49

Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:

Akzeptiert: 27. Juli 2024 | 17:49
ID: fb5b3fca-ae64-4fca-8e34-d6ea60f54f05

PD Dr. Jean-Yves Fournier
jean-yves.fournier@hopitalvs.ch
Sicherheitsstufe: E-Mail, Kontoauthentifizierung
(keine)

Signé par :

84E6D8A14E3B42E...


Signaturübernahme: Vorgegebener Stil
Mit IP-Adresse: 153.109.119.215

Gesendet: 27. Juli 2024 | 17:05
Eingesehen: 08. August 2024 | 12:50
Signiert: 08. August 2024 | 12:52

Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:

Akzeptiert: 08. August 2024 | 12:50
ID: 418a33da-8f5d-497f-b138-1ccfa005cb02

PD Dr. Mahmoud Messerer
mahmoud.messerer@chuv.ch
Sicherheitsstufe: E-Mail, Kontoauthentifizierung
(keine)

Signé par :

4A8F684E6FA9416...


Signaturübernahme: Auf Gerät gezeichnet
Mit IP-Adresse: 85.2.124.34
Mit Mobilgerät signiert

Gesendet: 27. Juli 2024 | 17:05
Eingesehen: 28. Juli 2024 | 07:50
Signiert: 28. Juli 2024 | 07:52

Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:

Akzeptiert: 28. Juli 2024 | 07:50
ID: 88c11a1e-73ef-46e5-b48c-e62565c2765a

Prof. Javier Fandino
javier.fandino@hirslanden.ch
Sicherheitsstufe: E-Mail, Kontoauthentifizierung
(keine)

Signiert von:

0FA282E2B1B649B...

Signaturübernahme: Auf Gerät gezeichnet
Mit IP-Adresse: 154.127.8.113
Mit Mobilgerät signiert

Gesendet: 27. Juli 2024 | 17:05
Eingesehen: 28. Juli 2024 | 10:26
Signiert: 28. Juli 2024 | 10:45

Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:

Akzeptiert: 28. Juli 2024 | 10:26
ID: 78914b89-a19e-4afc-82dd-7a5ca823d135

Prof. Philippe Bijlenga
philippe.bijlenga@hug.ch
Sicherheitsstufe: E-Mail, Kontoauthentifizierung
(keine)

Signed by:

61A823B48359426...

Signaturübernahme: Vorgegebener Stil
Mit IP-Adresse: 104.28.62.83
Mit Mobilgerät signiert

Gesendet: 27. Juli 2024 | 17:05
Eingesehen: 27. Juli 2024 | 18:58
Signiert: 27. Juli 2024 | 18:59

Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:

Unterzeichnereignisse	Signatur	Zeitstempel
-----------------------	----------	-------------

Akzeptiert: 27. Juli 2024 | 18:58
 ID: 20c516c9-9b5b-4826-93b5-5221fae0329d

Prof. Raphael Guzman
 raphael.guzman@usb.ch
 Chair Neurosurg

Sicherheitsstufe: E-Mail, Kontoauthentifizierung
 (keine)

DocuSigned by:

 D1714303E0214BF...

Signaturübernahme: Vorgegebener Stil
 Mit IP-Adresse: 178.197.202.10

Gesendet: 27. Juli 2024 | 17:05
 Erneut gesendet: 08. August 2024 | 17:42
 Eingesehen: 08. August 2024 | 23:21
 Signiert: 08. August 2024 | 23:22

Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:

Nicht über DocuSign angeboten

Prof. Ulf Schneider
 ulf.schneider@luks.ch

Sicherheitsstufe: E-Mail, Kontoauthentifizierung
 (keine)

Signiert von:

 9B5D2C2F971946D...

Signaturübernahme: Auf Gerät gezeichnet
 Mit IP-Adresse: 206.0.71.86
 Mit Mobilgerät signiert


Gesendet: 27. Juli 2024 | 17:05
 Eingesehen: 29. Juli 2024 | 00:06
 Signiert: 29. Juli 2024 | 00:07

Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:

Akzeptiert: 29. Juli 2024 | 00:06
 ID: e604eb4f-5ca1-4705-be14-d0aba7e31343

Prof. Urs Fischer
 urs.fischer@insel.ch
 Prof. Dr. med.

Sicherheitsstufe: E-Mail, Kontoauthentifizierung
 (keine)

DocuSigned by:

 BBBB1F0483DE4DD...

Signaturübernahme: Vorgegebener Stil
 Mit IP-Adresse: 161.62.252.40


Gesendet: 27. Juli 2024 | 17:05
 Eingesehen: 27. Juli 2024 | 18:32
 Signiert: 27. Juli 2024 | 18:32

Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:

Akzeptiert: 27. Juli 2024 | 18:32
 ID: eadfdb6d-7a64-4d35-a00a-0f8877c86fb2

Prof.Dr.med. Andreas Raabe
 andreas.raabe@insel.ch

Sicherheitsstufe: E-Mail, Kontoauthentifizierung
 (keine)

DocuSigned by:

 CECA2C25CB2D493...

Signaturübernahme: Vorgegebener Stil
 Mit IP-Adresse: 161.62.252.40

Gesendet: 27. Juli 2024 | 17:05
 Eingesehen: 05. August 2024 | 13:23
 Signiert: 05. August 2024 | 13:24

Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:

Akzeptiert: 05. August 2024 | 13:23
 ID: 073c5644-da5c-4dd0-954b-cd87be8a272a

Tim Hallenberger
 tim.hallenberger@usb.ch

Sicherheitsstufe: E-Mail, Kontoauthentifizierung
 (keine)

DocuSigned by:

 B6AED33749974E7...

Signaturübernahme: Hochgeladenes Signaturbild
 Mit IP-Adresse: 145.250.209.1

Gesendet: 27. Juli 2024 | 17:05
 Eingesehen: 27. Juli 2024 | 17:06
 Signiert: 27. Juli 2024 | 17:07

Vereinbarung bezüglich elektronischer Unterlagen und Signaturen:

Nicht über DocuSign angeboten

Vor-Ort-Unterzeichner – Ereignisse	Signatur	Zeitstempel
------------------------------------	----------	-------------

Bearbeiterversandereignisse	Status	Zeitstempel
-----------------------------	--------	-------------

Beauftragtenzustellereignisse	Status	Zeitstempel
-------------------------------	--------	-------------

Vermittlerversandereignisse	Status	Zeitstempel
Zertifizierter Versand - Ereignisse	Status	Zeitstempel
Kopienereignisse	Status	Zeitstempel
Zeugen-Ereignisse	Signatur	Zeitstempel
Notarereignisse	Signatur	Zeitstempel
Umschlagereignisse – Überblick	Status	Zeitstempel
Umschlag gesendet	Hash-codiert/verschlüsselt	27. Juli 2024 17:05
Zertifiziert zugestellt	Sicherheitsprüfung ausgeführt	27. Juli 2024 17:06
Signiervorgang abgeschlossen	Sicherheitsprüfung ausgeführt	27. Juli 2024 17:07
Abgeschlossen	Sicherheitsprüfung ausgeführt	12. August 2024 09:32
Zahlungen	Status	Zeitstempel
Vereinbarung bezüglich elektronischer Unterlagen und Signaturen		

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, University Hospital Basel (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact University Hospital Basel:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To advise University Hospital Basel of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at privacy@uhb.ch and in the body of such request you must state: your previous email address, your new email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from University Hospital Basel

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to privacy@uhb.ch and in the body of such request you must state your email address, full name, mailing address, and telephone number.

To withdraw your consent with University Hospital Basel

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to and in the body of such request you must state your email, full name, mailing address, and telephone number. . .

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify University Hospital Basel as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by University Hospital Basel during the course of your relationship with University Hospital Basel.

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, University Hospital Basel (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact University Hospital Basel:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: emanuel.madiou@usb.ch

To advise University Hospital Basel of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at emanuel.madiou@usb.ch and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from University Hospital Basel

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to emanuel.madiou@usb.ch and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with University Hospital Basel

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to emanuel.madiou@usb.ch and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify University Hospital Basel as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by University Hospital Basel during the course of your relationship with University Hospital Basel.